A drug containing a chelator with strong Zn ion-scavenging properties for the treatment of symptoms and diseases caused by microorganisms / diseases caused by toxins or neurotoxins / cancer / and several syndromes.

Abstract

Metalloproteins on the surface of pathogenic microorganisms have a high density of Zn ions, and these Zn ions help the pathogenic microorganisms bind to metal ions on metalloproteins on the surface of host cells (similar to how Zn ions find and bind to other metal ions in a battery with a Zn-other metal electrode pair). Pathogenic microorganisms and their fragments release Zn-rich products into the host body, and these Zn-rich products rapidly cause chelators with Zn ion-capturing properties (these are mainly derivatives of polyamines / aminopolycarboxylic acids) to completely capture the Zn ions, depleting these active chelators. When the active chelators are depleted, the Zn-rich products bind to host metalloproteins, causing most of the symptoms. Then the host body provides new active chelators, which sequester the Zn-rich products from the host metalloproteins, relieving most of the symptoms. The drug of the present invention contains chelators with strong Zn ion-capturing properties (these are derivatives of polyamines / aminopolycarboxylic acids) that have the following effects: - Rapidly reduces most symptoms, - Weakens microorganisms and causes them to lose their ability to bind to host cells, - Strengthens the host immune system, - Eliminates the accumulation of Zn-rich products from host metalloproteins and repels most symptoms, - Repels post-disease syndromes, etc. The drug of the present invention contains a [highly active chelator + agent that produces a strong physical effect (in the treated tissue)] for treating affected tissue (e.g., bacterial-infected tissue / necrotic tissue / fungal-infected tissue / benign tumors / cancerous tumors) with outstanding efficacy.

Description

Technical Field

[0001] The present invention belongs to the pharmaceutical field containing a chelating agent having the ability to retain [Zn ions / other heavy metal ions] for treating symptoms of diseases caused by pathogenic microorganisms and for preventing or treating diseases / toxins caused by pathogenic microorganisms and diseases / neurotoxins and chronic diseases caused by diseases / neurotoxins and chronic diseases caused by polyamine derivatives in the elderly or diseases / cancers / some other diseases / some syndromes / affected tissues (e.g., infected tissues / necrotic tissues / tissues containing many toxins / benign tumors / cancerous tumors) that weaken the immune system due to the decrease of polyamine derivatives in the elderly.

Background Art

[0002] Until now, biology / medicine has not known that pathogenic microorganisms and the [Zn / other transition metal]-rich products released from their fragments (referred to as [Zn / other transition metal]-rich products from pathogenic microorganisms) rapidly deplete chelators that have [Zn ion / other transition metal ion]-capturing characteristics (still having the activity to capture [Zn ions / other transition metal ions]), which means that chelators that play a role in resisting symptoms in the host body (the host is an animal / human) deplete [Zn ion / other transition metal] chelators. In a state of depletion of chelators with [metal ion]-capturing characteristics, [Zn / other transition metal]-rich products from pathogenic microorganisms bind to host metalloproteins, causing various symptoms (e.g., fatigue / runny nose / purulent sputum / diarrhea / dyspnea, etc.) / neurological symptoms (e.g., sore throat / cough / soft tissue pain / muscle pain / joint pain / bone tissue pain / eye pain / headache / blood viscosity / tissue fluid viscosity / alveolar fluid viscosity / blood coagulation / cytokine storm / respiratory failure / acute respiratory failure, etc.) and leading to long-term post-illness syndromes. [Zn / other transition metal]-rich products from primary pathogenic microorganisms are a source of Zn / other transition metals that cause rapid proliferation of secondary pathogenic microorganisms, and cause rapid proliferation and rapid size increase of cancer cells and cancerous tissues, weakening the patient's immune system during depletion of chelators with [Zn ion / other transition metal ion]-capturing characteristics. Depletion of chelators with [Zn ion / other transition metal ion]-capturing properties in the bodies of patients with certain chronic diseases (e.g., HIV / tuberculosis / other chronic diseases caused by pathogenic microorganisms / stage 3 and 4 cancers) weakens the immune system of these patients over the long term. Until now, biology / medicine has not known that a decrease in chelators with [Zn ion / other transition metal ion]-capturing properties in the elderly causes a weakening of the immune system over time, and polyamine derivatives in the bodies of obese individuals, in the form of fatty acid soap polyamine salts which are inactive forms that capture Zn ions / other metal ions, weaken the immune system of obese individuals. Therefore, when obese individuals suffer from diseases caused by pathogenic microorganisms, symptoms are severe, pathogenic microorganisms multiply rapidly, and the disease state of obese patients rapidly deteriorates / easily leads to death.

[0003] And until now, biology / medicine has not known the following: Cherators with [Zn ion / other transition metal ion] scavenging properties are drugs that help the host body recover rapidly by producing a series of effects outlined below. Therefore, until now, there have been no drugs containing chelators with [Zn ion / other transition metal ion] scavenging properties to prevent or treat the above symptoms / diseases. And until now, biology / medicine has not known the following: When a drug producing a strong physical effect + a chelator with [Zn ion / other transition metal ion] scavenging properties + a drug that does not create a foam structure in the affected tissue / a drug that creates a foam structure in the affected tissue] (or with the addition of other therapeutic active ingredients; collectively referred to as the chelator and other therapeutic active ingredients as therapeutic active ingredients) is introduced into affected tissue (e.g., infected tissue / necrotic tissue / fungally infected tissue / tissue containing highly viscous fluids / benign tumors / cancerous tumors), it increases the dispersion rate of the active ingredients in the treated tissue by tens to hundreds of times. This creates a dense structure in the affected tissue (e.g., structure of benign tumors / cancerous tumors / fungal-infected tissue) or a structure containing highly viscous fluids (e.g., infected tissue / necrotic tissue) that has lost its protective ability against pathogenic entities (e.g., pathogenic microorganisms / cancer cells) / virulence factors (e.g., toxins, and nutrients for pathogenic microorganisms / cancer cells) within the affected tissue, and the strong physical effect / [strong physical effect + foam structure] in the treated tissue helps the dense structure / highly viscous fluid-containing structure of the affected tissue, which makes it difficult to treat the affected tissue. Therefore, to date, there are no drugs for treating the above-mentioned affected tissue that have the components [a drug that produces a strong physical effect + a chelator with [Zn ion / other transition metal ion] capturing properties] / [a drug that produces a strong physical effect + a chelator with [Zn ion / other transition metal ion] capturing properties + a drug that creates a foam structure in the affected tissue].

[0004] And until now, biology / medicine has not known the following: Cherators with [Zn ion / other transition metal ion] scavenging properties are drugs that help sequester toxins / neurotoxins (the structure of toxins / neurotoxins requires the scavenging of [Zn ion / other transition metal ion] to bind to host metalotoproteins in order to cause poisoning) from host metalotoproteins, and neutralize the toxicity of toxins / neurotoxins produced by pathogenic microorganisms / from outside the host body. Therefore, until now, there are no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging properties to treat diseases caused by toxins / neurotoxins produced by pathogenic microorganisms / entering the host body from outside. And biology / medicine has not known the following: A decrease in polyamine derivatives in the bodies of the elderly increases the accumulation of Zn ions / other transition metal ions in tissues / nerve tissue / brain tissue, leading to dementia syndrome / tremor syndrome / blurred vision syndrome. Therefore, to date, there are no drugs whose active ingredients are chelators with strong [Zn ion / other transition metal ion] scavenging properties for treating the elderly and for helping to strengthen their immune systems. Furthermore, biology / medicine is unaware that chelators with strong [Zn ion / other transition metal ion] scavenging properties reduce the voltage of metalloproteins in living organisms within the patient's body. This occurs when the patient uses these drugs, and when the patient uses other drugs simultaneously with chelators with strong [Zn ion / other transition metal ion] scavenging properties, it greatly increases the effectiveness of the other drugs, thereby greatly reducing the dosage of the other drugs that need to be used.

[0005] Until now, biology / medicine has been unaware of the important role of chelators with strong [Zn ion / other transition metal ion] scavenging characteristics in the biological world (including the host body (which is an animal / human)). Until now, biology / medicine has been unaware of the important role of chelators with strong [Zn ion / other transition metal ion] scavenging characteristics in the biological world (including the host body (which is an animal / human)), biology / medicine has been unaware of the major changes involving [Zn / other transition metals] and chelators with [Zn ion / other transition metal ion] scavenging characteristics when the host suffers from various diseases, and biology / medicine has been unaware of the valuable benefits of the physical effects produced in the patient's body / affected tissue that greatly contribute to greatly increasing the effectiveness of treating various diseases / affected tissues. Therefore, until now, there are no drugs containing chelators with strong [Zn ion / other transition metal ion] scavenging characteristics for treating many different diseases. Therefore, to date, there are no drugs containing [a chelator with strong [Zn ion / other transition metal ion] scavenging characteristics + a drug that produces a strong physical effect] / [a chelator with [Zn ion / other transition metal ion] scavenging characteristics + a drug that produces a strong physical effect in the treated tissue + a drug that creates a foam structure in the treated tissue] for the treatment of various diseases / different affected tissues. Furthermore, biology / medicine is unaware that synthetic chelators, which are salts made from polyamines and acids with sulfur functional groups in the molecule, are substances that have the ability to rapidly alleviate symptoms / help the patient's body recover rapidly, and the ability of the above synthetic chelators to rapidly eliminate symptoms / help the patient's body recover rapidly exceeds the ability of natural chelators present in the host body (mainly histidine / lysine / arginine derivatives) by tens to hundreds of times. Therefore, to date, there are no drugs containing the above synthetic chelating agents for the treatment of different symptoms / different diseases.

[0006] More specifically, until now, biology / medicine has been largely unaware of [Zn ions / other transition metal ions], chelators with [Zn ion / other transition metal ion]-capturing properties, and physical effects, leading to the following situation: There are no drugs whose active ingredient is a [strong [Zn ion / other transition metal ion]-capturing chelator] for various diseases / syndromes / weakened immune systems / diseases caused by toxins and neurotoxins / cancer / treatment of affected tissues, etc.; there are no drugs whose active ingredient is a [strong [Zn ion / other transition metal ion]-capturing chelator + drug that produces strong physical effects]; and there are no drugs whose active ingredient is a [strong [Zn ion / other transition metal ion]-capturing chelator + drug that produces strong physical effects + drug that produces strong physical effects + drug that produces microbubbles]. Specifically, until now, biology / medicine has been unaware of the following, and until now, the following situation exists.

[0007] - Factors and conditions that cause symptoms of diseases caused by microorganisms, and the status of drugs that treat symptoms in a manner that eliminates the factors that cause them. Until now, biology / medicine has not known the factors and conditions that cause symptoms in microorganism-induced diseases, such as various symptoms / different neurological symptoms / blood viscosity or tissue fluid viscosity or alveolar fluid viscosity / blood coagulation / cytokine storm / respiratory failure / acute respiratory failure, caused by [Zn / other transition metal ion]-rich products (referred to as [Zn / other transition metal ion]-rich products from pathogenic microorganisms and their fragments) released into the host body. In particular, when a patient's body has low levels of chelators with [Zn ion / other transition metal ion]-capturing characteristics (these chelators are mainly polyamine derivatives, e.g., histidine / lysine / arginine / putrescine / cadaverine / spermidine), or is depleted of these chelators (because these chelators have already completely captured Zn ions / other transition metal ions), these [Zn / other transition metal ion]-rich products bind to metalloproteins in host cells / tissues / nerve tissue / brain tissue, causing the symptoms described above. Therefore, to date, there are no drugs that help sequester the aforementioned Zn-rich products / other transition metal-rich products from host metalloproteins in host cells / tissues / nerve tissue / brain tissue, and that help eliminate these Zn-rich products / other transition metal-rich products from the host body through urine (only drugs that treat symptoms by reducing the perception of symptoms (e.g., reducing the perception of tissue pain / muscle pain / headache)).

[0008] - Factors and conditions that cause rapid proliferation of pathogenic microorganisms (including primary and secondary pathogenic microorganisms), and the status of drugs that inhibit / kill these pathogenic microorganisms. To date, biology / medicine has not known the factors that cause secondary microorganisms to rapidly proliferate in a patient's body due to Zn / other transition metal-rich products from pathogenic microorganisms that cause secondary microorganisms to obtain Zn / other transition metal raw materials, thereby depleting chelators with [Zn ion / other transition metal ion] scavenging characteristics. When the host body is depleted of chelators with [Zn ion / other transition metal ion] scavenging characteristics, secondary pathogenic microorganisms can easily utilize these Zn / other transition metal-rich products from pathogenic microorganisms (primary pathogenic microorganisms) as a source of Zn / other transition metals for rapid proliferation of secondary pathogenic microorganisms. Therefore, to date, there are no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging characteristics to inactivate Zn / other transition metal-rich products from pathogenic microorganisms (which cause primary disease) so that secondary pathogenic microorganisms cannot proliferate.

[0009] - Factors and conditions that cause severe symptoms in obese / elderly / medically ill individuals when suffering from microbially caused diseases, and the status of drugs for treating microbially caused diseases in obese / elderly / medically ill individuals. To date, biology / medicine has not known the following: Polyamine derivatives in the bodies of obese individuals are in the form of soap aliphatic salts with a very weak ability to capture Zn ions / other transition metal ions; therefore, when suffering from diseases caused by pathogenic microorganisms, the bodies of obese individuals lack highly active polyamine derivatives to prevent symptoms from occurring. The bodies of the elderly / those with underlying medical conditions have low levels of polyamine derivatives / [low polyamine derivatives that still have the ability to capture Zn ions / other transition metal ions], which causes the elderly / those with underlying medical conditions to have severe symptoms when suffering from diseases caused by microorganisms. Therefore, to date, there are no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] capturing characteristics to help the elderly / those with underlying medical conditions avoid severe symptoms when suffering from diseases caused by pathogenic microorganisms.

[0010] - Factors and conditions that weaken the immune system in several diseases, and the status of drugs that treat a weakened immune system. Until now, biology / medicine has not known the following: Microorganisms that cause chronic diseases such as HIV / tuberculosis / other chronic diseases / stage 3-4 cancer tissue are biological factories that release Zn / other transition metal-rich products. These continuously enter the host body, keeping the host body in a state of constant low levels of chelating [Zn ions / other transition metal ions], causing a lack of these chelators to bind to Cu / Mg / Ca ions in the structure of antibacterial alkaline peptides / antibody proteins / bactericidal proteins in leukocytes, reducing the ability of antibacterial alkaline peptides / antibody proteins / bactericidal proteins in leukocytes to kill pathogenic microorganisms, and sequestering Zn ions / other transition metal ions on the surface of metastatic cancer cells that have emerged from pathogenic microorganisms / cancer tissue, thus preventing metastatic cancer cells that have emerged from pathogenic microorganisms / cancer tissue from binding to host metalloproteins and causing disease / metastasis to healthy tissue. Therefore, to date, there are no pharmaceuticals that use the aforementioned weakened immune system as an active ingredient, specifically a chelator with [Zn ion / other transition metal ion] scavenging properties.

[0011] - Conditions that weaken the immune system in the elderly, the status of drugs that strengthen the immune system in the elderly, and conditions that cause dementia syndrome / tremor syndrome / cataract syndrome in the elderly, and drugs to treat these syndromes. Until now, biology / medicine has been unaware of the following: The bodies of elderly people gradually decrease the amount of polyamine derivatives that are chelators with [Zn ion / other transition metal ion] scavenging properties. Consequently, over time, Zn / other transition metal-rich products from food / pathogenic microorganisms gradually accumulate in metalloproteins in the tissues of the elderly / eye tissue / nerve tissue / brain tissue, weakening the immune system and causing the appearance of dementia syndrome / tremor syndrome / cataract syndrome, with the condition worsening over time. Therefore, to date, there have been no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging properties to strengthen the immune system of the elderly, and there are no drugs to effectively treat dementia syndrome / tremor syndrome / cataract syndrome in the elderly.

[0012] - Conditions and factors that cause dementia syndrome / tremor syndrome / cataract syndrome in the elderly, and the status of medications for treating these syndromes. Until now, biology / medicine has not known the following: The amount of polyamine derivatives, which are chelators with the characteristic of capturing [Zn ions / other transition metal ions], decreases over time in the bodies of elderly individuals, increasing the accumulation of [Zn ions / transition metal ions] in cells / tissues / nerve tissue / brain tissue, and causing dementia syndrome / tremor syndrome / cataract syndrome in the elderly. Therefore, to date, there are no drugs whose active ingredient is a chelator with the characteristic of capturing [Zn ions / other transition metal ions] that treat dementia syndrome / tremor syndrome / cataract syndrome in the elderly in a way that eliminates the aforementioned accumulation.

[0013] - Conditions and factors that weaken the immune system in the elderly, and the status of drugs for treating the weakened immune system in the elderly. Until now, biology / medicine has been unaware that the amount of polyamine derivatives, which are chelators with [Zn ion / other transition metal ion]-capturing properties, in the bodies of the elderly gradually decreases over time, increasing the accumulation of [Zn ion / transition metal ion] in cells / tissues / nerve tissue / brain tissue, causing pathogenic microorganisms to not be inactivated upon entering the body and to have an available source of Zn / transition metal material for rapid proliferation, lacking chelators with [Zn ion / other transition metal ion]-capturing properties to bind to Cu ions / Mg ions / Ca ions in the structure of antibacterial alkaline peptides / antibody proteins / bactericidal proteins in leukocytes, reducing the ability of antibacterial alkaline peptides / antibody proteins / bactericidal proteins in leukocytes to kill pathogenic microorganisms, lacking the aforementioned chelators to sequester Zn ions / other transition metal ions on the surface of pathogenic microorganisms, and weakening the immune system of the elderly. Therefore, to date, there are no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging characteristics that strengthen the immune system of the elderly by eliminating the above accumulation and creating the above binding.

[0014] - Factors and conditions that increase the lifespan of the host (animal / human), and the status of drugs that increase lifespan. Until now, biology / medicine has not known that chelators with [Zn ion / other transition metal ion] scavenging properties help strengthen the immune system of the elderly (as mentioned above) and help the elderly body eliminate the accumulation of Zn ion-other metal ion complexes in tissues (as mentioned above), contributing to increased lifespan and improved health in the elderly. The aforementioned chelators also break Zn crosslinks / other transition metal crosslinks / Zn-other transition metal complex crosslinks on metalloproteins of telomeres during cell division, reducing the likelihood that telomeres will stick together at the end of the cell division process, causing telomeres to gradually shorten, and thus contributing to increased lifespan in the elderly (the bodies of long-lived turtles are rich in polyamine derivatives). This helps them have a strong immune system, helps them live longer, and helps them not die when they eat foods containing toxins / neurotoxins (e.g., rat poison). These eggs are rich in polyamine derivatives, and therefore they do not coagulate when boiled (mammalian / human animal semen is rich in spermidine / spermine derivatives, and they do not coagulate when heated above 100 degrees Celsius). Therefore, to date, there are no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging properties to help increase the immune system / health / lifespan of the elderly.

[0015] Factors and conditions that worsen Alzheimer's / Parkinson's disease after exposure to microbially caused diseases in Alzheimer's / Parkinson's disease patients, the status of drugs that prevent the worsening of Alzheimer's / Parkinson's disease by eliminating factors that worsen Alzheimer's / Parkinson's disease, and the status of drugs that alter the conditions that worsen the disease. Until now, biology / medicine has not known the following: Patients with Alzheimer's / Parkinson's disease have chelators with low levels of [Zn ion / other transition metal ion] scavenging characteristics. Therefore, when these diseases are caused by pathogenic microorganisms or when consuming foods rich in Zn / other transition metals, the accumulation of Zn ions / transition metal ions in the nerve tissue / brain tissue of these patients increases, worsening these diseases. Consequently, to date, there are no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging characteristics that help prevent the worsening of Alzheimer's / Parkinson's disease in the above cases by eliminating the aforementioned accumulation.

[0016] - Conditions and factors that cause post-illness syndromes (from diseases caused by pathogenic microorganisms), and the status of drugs for treating these syndromes. Until now, biology / medicine has not known that when a host suffers from a disease caused by pathogenic microorganisms, its body has low levels / depletion of chelators with [Zn ion / other transition metal ion] scavenging properties, and Zn-rich products / other transition metal-rich products accumulate on metalloproteins in host cells / tissues / nerve tissue / brain tissue, leading to post-disease syndromes (e.g., post-Covid syndrome). Therefore, to date, there have been no drugs whose active ingredient is a chelator with strong [Zn ion / other transition metal ion] scavenging properties to treat post-disease syndromes (from diseases caused by pathogenic microorganisms) in a way that removes the above accumulation.

[0017] - The physical structure of the affected tissue (e.g., infected tissue / necrotic tissue / fungally infected tissue / tissue containing fluids with many toxins / dark-colored benign tumors / cancerous tumors) plays a role as a structure that helps protect virulence factors / pathogenic entities within these physical structures. Drug situations cause these physical structures to lose their ability to protect virulence factors / pathogenic entities within them. Until now, biology / medicine has not known the following: The dense structure / highly viscous fluid-containing structure of affected tissue (e.g., infected tissue / necrotic tissue / fungally infected tissue / tissue containing highly viscous fluids with many toxins / dark-colored benign tumors / cancerous tumors) protects the virulence factors / pathogenic entities within these structures, making it extremely difficult for active ingredients to thoroughly contact the virulence factors / pathogenic entities within these structures. Therefore, to date, there are no drugs that produce a sufficiently strong physical effect in the affected tissue to help increase the rate of active treatment ingredients into the affected tissue and create thorough contact between the treatment active ingredients and the virulence factors / pathogenic entities within the treated tissue.

[0018] Transition metal ion crosslinks / transition metal ion Zn-other transition metal ion complex crosslinks are located between metal ions on metalloproteins in continuously developing cancer cells / cancer cells / cancerous tissues. The situation regarding drugs for treating cancerous tissue by breaking these crosslinks is unclear. Until now, biology / medicine has not known the following: Cancer cells / cancer syncytium / cancer tissue that continuously increase in size are caused by transition metal ion crosslinks / Zn ion-other transition metal ion complex crosslinks located between metal ions on metalloproteins on [cancer cells / cancer syncytium / cancer tissue], which cause [cancer cells / cancer syncytium / cancer tissue] to continuously increase in size. A solution containing [a chelator with strong [Zn ion / other transition metal ion] scavenging characteristics + a high concentration of polyol] (unknown solution) / a solution containing [a chelator with strong [Zn ion / other transition metal ion] scavenging characteristics + a high concentration of polyol + peroxide (peroxide to create a foam structure in the treated tissue and oxidize the aforementioned crosslinks)], when present in cancerous tissue, breaks down many of the above crosslinks in the cancerous tissue (killing cancer cells / disintegrating cancer syncytium / reducing the size of cancerous tissue). Therefore, to date, there are no drugs for treating cancerous tissue (or benign tumors) using solutions containing [a chelator with strong [Zn ion / other transition metal ion] scavenging properties + high concentration of polyol] / [a chelator with strong [Zn ion / other transition metal ion] scavenging properties + high concentration of polyol + peroxide].

[0019] - The way in which the structure of external toxins / external neurotoxins binds to host metalloproteins and causes toxicity, and the status of drugs for treating diseases caused by external toxins / external neurotoxins. To date, biology / medicine has not known the structure of external toxins / external neurotoxins when they are present in the host body. They require the capture of [Zn ions / other transition metal ions] to bind to the host's metalloproteins, and then cause toxicity to the host. Therefore, to date, there are no drugs to treat the above structures by isolating them from the host's metalloproteins and by inactivating the Zn ions / transition metal ions on the above structures in order to eliminate the toxicity of external toxins / external neurotoxins. Consequently, to date, there are no drugs that are chelators with strong [Zn ion / other transition metal ion] capturing properties as active ingredients for inactivating toxins / neurotoxins and treating diseases caused by external toxins / external neurotoxins.

[0020] - Factors and conditions that increase the effectiveness of disease treatment for several drugs, as well as the status of chelating agents used in conjunction with disease treatment drugs to increase their effectiveness. To date, biology / medicine has not known how polyamine derivatives of the host body (these are chelators with [Zn ion / other transition metal ion] scavenging properties) that reduce the voltage of the electrode pairs of host metalloproteins present in the host body / reduce the polarity of host metalloproteins present in the host body, thereby increasing the permeability of disease-treating drugs into the body, can increase the therapeutic efficacy of disease-treating active ingredients and reduce the dose of disease-treating active ingredients required for treatment. Therefore, to date, there are no drugs in which the active ingredient used in conjunction with disease-treating drugs is a [[Zn ion / other transition metal ion] scavenging property] to increase the efficacy of disease-treating active ingredients and reduce the dose of disease-treating drugs required for use, and there are no drugs containing a [[Zn ion / other transition metal ion] scavenging property + active disease-treating ingredient] to increase the efficacy of active disease-treating ingredients and reduce the dose of disease-treating drugs required for use.

[0021] - Factors and conditions that increase the ability of bacteria that already possess the ability to resist antibiotics, as well as drug situations that cause bacteria that are already resistant to antibiotics to lose their ability to resist antibiotics. To date, biology / medicine has not known that chelators with [Zn ion / other transition metal ion] scavenging properties are drugs that cause microorganisms already capable of resisting antibiotics to lose this ability. Therefore, to date, there are no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging properties for use in conjunction with antibiotics to kill the aforementioned disease-causing microorganisms that have lost their ability to resist antibiotics, and to help reduce the dose of antibiotics required to treat diseases caused by pathogenic microorganisms. To date, it is not possible to include drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging properties for use in conjunction with antibiotics to cause antibiotic-resistant pathogenic microorganisms to lose their resistance, and to help reduce the dose of antibiotics required to treat diseases caused by pathogenic microorganisms. Alternatively, there are no drugs in the form of a chelator with [[Zn ion / other transition metal ion] scavenging features + antibiotic (low amount of antibiotic) to cause antibiotic-resistant pathogenic microorganisms to lose their ability to resist antibiotics, and to help reduce the dose of antibiotic required to treat diseases caused by these pathogenic microorganisms. Therefore, to date, there are no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging features for use concurrently with antibiotics to cause antibiotic-resistant pathogenic microorganisms to lose their ability to resist antibiotics, and to help reduce the dose of antibiotic required to treat diseases caused by these pathogenic microorganisms. Alternatively, there are no drugs in the form of a chelator with [[Zn ion / other transition metal ion] scavenging features + antibiotic (low antibiotic content) to cause antibiotic-resistant pathogenic microorganisms to lose their ability to resist antibiotics.

[0022] - Factors and conditions that reduce the voltage measured by a metal-Zn-Cu-metal electrode pair in the patient's body / affected tissue caused by pathogenic microorganisms / tissue due to mechanical damage, as well as the status of drugs that reduce the above measured voltage to treat symptoms such as pain / inflammation / fever. Until now, biology / medicine has not known that the voltage measured by a metallic Zn-metallic Cu electrode pair in the fluids of a patient's body, the voltage measured in the patient's skin, affected tissues caused by pathogenic microorganisms, or tissues caused by mechanical injury dramatically increases, leading to fever, inflammation, tissue pain, muscle pain, joint pain, and headache due to the depletion of chelators with [Zn ion / other transition metal ion]-capturing properties. Therefore, to date, there are no drugs containing chelators with [Zn ion / other transition metal ion]-capturing properties to treat fever, inflammation, tissue pain, muscle pain, joint pain, and headache.

[0023] - Factors and conditions that cause anaphylactic shock during drug injection / intravenous infusion / blood transfusion / tissue transplantation, and the status of drugs for treating anaphylactic shock in a manner that eliminates the factors that cause anaphylactic shock. So far, biology / medicine has been unaware of the following. In those with very low blood levels of polyamine derivatives, when drugs are injected / vaccines / intravenous drips / blood transfusions / tissue transplants / contact with foreign allergens, these foreign substances entering the body will mobilize chemokines. Then, the chemokines release ceruloplasmin that is rich in Zn, and at the same time, antibacterial alkaline peptides / antibodies / rich in Cu, but in a state where there is a lack of binding of polyamine derivatives to the structural Cu ions in them, which causes them to become weak Cu chelates (weak Cu capture). Instead, they are strong Cu chelates (strong Cu capture), which causes them to release Cu-rich products into the host body. The above-mentioned Zn-rich products and the above-mentioned Cu-rich products deplete chelators with [Zn ion / other transition metal ion] capture characteristics. In this depleted state, the Cu-Zn complex product becomes extremely toxic to host cells, and the Cu-Zn complex binds to the Fe ions of cells / red blood cells / alveolar cells, causing the cells / red blood cells / alveolar cells to lose their ability to exchange O2 / causing many neurological symptoms and anaphylactic shock. Therefore, so far, there is no drug whose active ingredient is a chelator with [Zn ion / other transition metal ion] capture characteristics for treating anaphylactic shock caused by drug injection / vaccine injection / intravenous drip / blood transfusion / tissue transplant / foreign allergens and for neutralizing the toxicity of the above-mentioned Zn-Cu complex.

[0024] - Conditions and factors that prevent the spread of microorganisms causing infectious diseases, and the situation of drugs / products for environmental treatment to prevent the spread of infectious diseases. So far, biology / medicine has been unaware of the following. Chelators with [Zn ion / other transition metal ion] capture characteristics block [Zn ion / other transition metal ion] on metalloproteins on the surface of pathogenic microorganisms (on the surface of spike proteins of pathogenic viruses in the case of pathogenic viruses), causing the pathogenic microorganisms to lose their ability to spread diseases to other hosts. Therefore, so far, there are no drugs / products for environmental treatment (spraying on the environment with infectious diseases / wiping the surface in the environment) containing the components [chelator with [Zn ion / other transition metal ion] capture characteristics + water] / [chelator with [Zn ion / other transition metal ion] capture characteristics + propylene glycol / glycerol + water].

[0025] The -form structure contains [high concentration of polyol + chelating agent + low water content] to increase the permeation rate of the active ingredient of the drug into the diseased tissue having a dense structure / high-viscosity fluid-containing structure. And the situation of drugs creating a foam structure containing [high concentration of polyol + chelator + low concentration of water]. So far, biology / medicine has been unaware of the following. For diseased tissue, when creating a foam structure containing [high concentration of polyol + chelator + peroxide + low concentration of water], pathogenic entities (such as pathogenic microorganisms / cancer cells / toxins) in the treated tissue reside in thin walls containing [high concentration of polyol + chelator + peroxide + low concentration of water] created by minute bubbles, causing the pathogenic entities / pathogenic factors to die rapidly / lose their activity rapidly, and the diseases of the tissue (such as infected tissue / necrotic tissue / fungal-infected tissue / tissue containing fluid with many toxins / benign tumor / cancerous tumor) to heal rapidly. At the same time, the high concentration of chelator and polyol will also help to relieve pain during treatment / reduce tissue inflammation. Therefore, so far, there are no drugs having the component [high concentration of polyol + chelator + peroxide + low concentration of water] for treating the above-mentioned diseased tissue.

[0026] - Factors and conditions that exacerbate many disease types (e.g., cancer / diseases later caused by secondary microbial infections / arthritis / many other underlying conditions) in individuals with post-illness syndromes (e.g., post-Covid syndrome), as well as the status of medications to prevent the exacerbation of the aforementioned many disease types. Until now, biology / medicine has not known that, after several diseases caused by pathogenic microorganisms (e.g., Covid-19), particularly in individuals with low levels of polyamine derivatives in the blood, Zn ion-other transition metal ion complexes accumulate very persistently on metalloproteins in host cells / tissues / joint tissue / nerve tissue / brain tissue, and these accumulations cause rapid exacerbation of many diseases (e.g., cancer / diseases later caused by secondary microbial infections / arthritis / many other underlying conditions). Therefore, to date, there have been no drugs whose active ingredient is a chelator with [Zn ion / other transition metal ion] scavenging properties to remove the above accumulations in order to prevent the exacerbation of many of the diseases (e.g., those mentioned above).

[0027] - The chelator's ability to dissolve Zn-blood complexes (or Zn-peptide complexes) (this ability suggests an ability to alleviate symptoms), and the safety of the chelator having [Zn ion / other transition metal ion] scavenging characteristics, which are polyamine aminopolycarboxylate / Mg aminopolycarboxylate / Ca aminopolycarboxylate. Until now, biology / medicine has not known that the ability of synthetic chelators [polyamine aminopolycarboxylates / Mg aminopolycarboxylates / Ca aminopolycarboxylates / salts made from an acid having a sulfur functional group on the molecule and a polyamine / salts made from an acid having at least two carboxyl groups on the molecule and a polyamine having at least four nitrogen functional groups on the molecule] to dissolve Zn-blood complexes (and also to alleviate symptoms) is higher than that of natural chelators present in the host body (e.g., lysine phosphate / lysine chloride / arginine phosphate / arginine chloride), being 80 to 200 times more effective at dissolving Zn-blood complexes. Therefore, to date, there are no drugs containing polyamine aminopolycarboxylates / Mg aminopolycarboxylates / Ca aminopolycarboxylates / salts made from an acid with a sulfur functional group on the molecule and a polyamine / salts made from a polyamine with at least four nitrogen functional groups on the molecule and an acid with at least two carboxyl groups on the molecule to treat various diseases by sequestering [Zn / other transition metal ions]-rich products from host metalloproteins, to treat these different diseases, and to treat severe / critical cases of these different diseases (therefore, until now, treatment of symptoms has not been more effective (because current drugs do not eliminate the factors that cause symptoms, and can only reduce the perception of pain caused by the symptoms)).

[0028] - The ability of several combinations of chelators with strong [Zn ion / other transition metal ion] capture characteristics to kill bacteria / fungi far surpasses that of antibiotics / antifungal agents. Until now, biology / medicine has not known that the ability of several combinations of chelators with strong [Zn ion / other transition metal ion] scavenging properties to kill bacteria / fungi, combined with the safety of these combinations for the host (the host is an animal / human), far surpasses the ability of antibiotics / antifungal agents. Therefore, to date, there are no drugs containing chelator combinations to replace antibiotics and antifungal agents.

[0029] For example, Patent Document 1, by author Barry, Michael Wells, has the patent application title "Use of trientine and penicilamine as countermeasure to metal contamination" and has a priority date of July 27, 2007. This provides a method for minimizing / preventing / treating the negative effects of excessive exposure to metal contaminants by using trientine or penicilamine, or derivatives thereof. Contaminated metals result from the host being exposed to sources of metal in the environment. The use of trientine or trientine derivatives in Patent Document 1 is unrelated to the pharmaceutical purposes of the present patent application's agents containing Zn scavenging chelators for treating symptoms / diseases / several other diseases caused by microorganisms.

[0030] Alternatively, for example, Patent Document 2 has the patent application title "Use of trientine to deliver copper to ischemic tissue" by author Yujian Jame Kang, with a priority date of October 24, 2015. Herein, the invention provides a method of using trientine for the purpose of delivering Cu to ischemic cardiac tissue in order to increase intracellular Cu levels in the cardiac tissue of patients with cardiac disorders caused by ischemic cardiac tissue. The use of trientine or trientine derivatives in this patent application is unrelated to the pharmaceutical purposes of the agents relating to this patent application that contain Zn scavenging chelators for treating symptoms / diseases / several other diseases caused by microorganisms.

[0031] Some inventions use metal chelates to inhibit the growth of microorganisms. For example, Patent Document 3, entitled "Antimicrobial chelates," authored by Robert Thompson, priority date November 3, 2004. This proposes a method for inhibiting the growth of microorganisms, including bacteria and fungi, by Zn chelates. During the research process of the invention (including the patent application agent containing a chelator with strong Zn ion-capturing characteristics), culture experiments of microorganisms that decompose organic matter (including bacteria whose cytium decomposes organic matter in the form of small blocks, and fungi whose cytium decomposes organic matter in the form of small fibers) showed the following: Zn chelate / Fe chelate has little ability to inhibit organic matter-degrading microorganisms, Na / K chelate has a weak ability to inhibit organic matter-degrading microorganisms, Mg chelate / Ca chelate / Cu chelate has a very strong ability to inhibit organic matter-degrading microorganisms, and combinations [Cu chelate + Mg chelate / Ca chelate + polyamine derivative] have a strong ability to inhibit organic matter-degrading microorganisms (far exceeding the inhibitory ability of most current antibiotics). The same is true for the ability to inhibit pathogenic microorganisms on open wounds of infected skin in animals (the infected skin animals used in the experiments were marine worms / Sipunculid worms (contained in a can with a moisturizer and used as fishing bait)) / on open wounds of infected tissue in human skin. Pathogenic microorganisms (including pathogenic fungi) require Zn as a Zn derivative to grow. Therefore, only chelators that have the ability to capture Zn ions have the ability to inhibit their growth, and Zn chelate does not have this ability. This means that the proposed method of inhibiting the growth of microorganisms, including bacteria and fungi, by using the Zn chelate of the above invention cannot yield practical results (according to the experiments / theories of this patent application).

[0032] Alternatively, for example, there is Patent Document 4, with the French title "Composition antibioti comprenant des betalacamines et des agents chelateurs ionniques" by author Hesheng Zhang. This proposes an antibiotic compound comprising at least one β-lactam antibiotic and at least one ion chelate. The antibiotic compound comprises at least one β-lactam antibiotic and at least one ion chelate, the ion chelate being disodium EDTA. This antibiotic compound requires a β-lactam antibiotic combined with a chelate ion to produce an antibiotic that is more effective than the β-lactam antibiotic. In Patent Document 4, disodium EDTA is used, and disodium EDTA is highly toxic to host cells (the host is animal / human). An experiment in which Boraras micros fish were kept in water with 300 ppm disodium EDTA showed the following: The fish died in less than 24 hours, but when Boraras microstratus fish were kept in water containing 800 ppm EDTA Cu / 3000 ppm EDTA Mg / 12000 ppm EDTA Ca, the fish did not die after 10 days. For healthy host cells to function normally, healthy animal / human cell metalloproteins require Mg ions / Ca ions / Cu ions / Fe ions / Zn ions / other heavy metal ions in their active form (not sequestered by chelator types that tightly capture them), but EDTA disodium (and EDTA dipotassium) is toxic to host cells due to the non-selective capture of those metal ions caused by EDTA disodium tightly capturing Mg ions / Ca ions / Cu ions / Fe ions / Zn ions / other heavy metal ions.

[0033] Alternatively, for example, there is Patent Document 5, entitled “Treatment of tumor,” by Russell Talor and Paul Crees, with a priority date of May 15, 2004. This invention uses a chelating agent (metal ion chelating agent) to produce a drug for preventing / treating cancer via bacteria, by a chelating agent that can capture at least one metal ion provided by bacteria to cancer, which depend on this metal ion for survival. Here, the chelating agent has the ability to capture Ca ions. In the implementation example, the chelating agent used is disodium EDTA, which is (as mentioned above) highly toxic to healthy cells and readily damages healthy host cells. At the same time, this patent application is not new, as the use of sodium EDTA has long been used as a food preservative, and sodium EDTA was introduced in the United States in 1999, in 1953, for medical use and is also on the World Health Organization's list of essential medicines. However, EDTA sodium calcium is not included in drugs for directly treating symptoms caused by pathogenic microorganisms / drugs for treating diseases with neurological symptoms caused by pathogenic microorganisms (e.g., diseases caused by SARS-Covid-2 virus) / drugs for directly treating diseases caused by the accumulation of [Zn / Zn-heavy metal complexes] in the host body / host tissues.

[0034] Generally, the conventional technology is as follows: Until now, biology / medicine has not known the following: When a host suffers from a disease caused by pathogenic microorganisms, [Zn derivatives / other transition metal derivatives / other Zn-rich peptides and other transition metal-rich peptides / other Zn-rich proteins and other transition metal-rich proteins] are transitions of [Zn / other transition metal-rich products] that bind to host metalloproteins, causing symptoms, leading to post-disease syndromes, and providing a source of Zn / other transition metal material for secondary pathogenic microorganisms. Secondary pathogenic microorganisms use high concentrations of [Zn ions / other transition metal ions] on their surface to bind to metalloproteins on the surface of host cells / receptors on the host cell membrane. Therefore, until now, there have been no drugs containing chelators with the following [Zn ion / other transition metal ion] scavenging characteristics. These chelators (chelator drugs) work by sequestering [Zn / other transition metal]-rich products and sequestering pathogenic microorganisms from host metalloproteins, thereby inactivating pathogenic microorganisms that have not yet bound to host metalloproteins, and removing the accumulation of Zn / transition metal ions in host tissues for the treatment of symptoms of diseases caused by primary and secondary pathogenic microorganisms, as well as for the treatment of all diseases caused by microorganisms and for the treatment of post-disease syndromes.

[0035] -Until now, biology / medicine has not known that when pathogenic microorganisms / metastatic cancer cells from cancerous tissue / toxins and neurotoxins (including external toxins / external neurotoxins) are present in the host body, their structures bind to host metalloproteins after capturing Zn ions / other transition metal ions in the host body, causing disease / cancer metastasis / toxicity. Furthermore, biology / medicine has not known that these structures are sequestered and inactivated from host metalloproteins by chelators with strong [Zn ion / other transition metal ion] capturing properties. Therefore, to date, there are no drugs containing chelators with strong [Zn ion / other transition metal ion] capturing properties for treating diseases caused by pathogenic microorganisms / cancer metastasis / diseases caused by toxins and neurotoxins.

[0036] -Until now, biology / medicine has not known the following: [Sufficiently strong multiple physical effects / form structures] appear in tissue treated with a drug containing a drug that generates sufficiently strong physical effects / form structures (treated affected tissue), increasing the dispersion rate of the active treatment component into the treated tissue by tens to hundreds of times, thereby helping the treatment active component overcome the protection of the dense structure / high-viscosity fluid-containing structure of the affected tissue, which is a structure that protects the virulence factors / pathogenic entities in the affected tissue. Therefore, until now, there have been no drugs containing [treatment active component + drug that generates sufficiently strong physical effects] / [treatment active component + drug that generates sufficiently strong physical effects + drug that generates foam structures (e.g., peroxide)] for treating affected tissue (e.g., infected tissue / necrotic tissue / fungal infected tissue / affected tissue containing fluids with many toxins / benign tumors / cancerous tumors).

[0037] -Until now, biology / medicine has not known the following: A weakened immune system is caused by a decrease / depletion of chelators with strong [Zn ion / other transition metal ion] scavenging characteristics in the host body, resulting in a lack of these chelators to bind to Cu ions / Mg ions / Ca ions in the structure of antibacterial alkaline peptides / antibody proteins / bactericidal proteins in leukocytes, reducing their ability to kill pathogenic microorganisms and causing the host immune system to weaken its ability to kill pathogenic microorganisms (meaning the host immune system is weakened). Therefore, until now, there have been no drugs containing chelators with strong [Zn ion / other transition metal ion] scavenging characteristics to treat weakened immune systems caused by chronic disease / aging.

[0038] -Until now, biology / medicine has not known that in many different treatment agents when combined with a chelator having strong [Zn ion / other transition metal ion] scavenging properties, the amount of the active ingredient of the different treatment agent required for treatment is very low (but the treatment efficacy is also increased). Therefore, until now, there have been no drugs in the form of combination [active treatment ingredient + chelator having strong [Zn ion / other transition metal ion] scavenging properties].

[0039] -Until now, biology / medicine has not known that pathogenic microorganisms resistant to antibiotics will lose this ability when a combination of [antibiotic resistant by the pathogenic microorganism + a chelator with strong [Zn ion / other transition metal ion] scavenging characteristics] is present in the host body. Therefore, to date, there is no combination drug in the form of [antibiotic + a chelator with strong [Zn ion / other transition metal ion] scavenging characteristics] for treating diseases caused by antibiotic-resistant pathogenic microorganisms.

[0040] -Until now, biology / medicine has not known that many strong physical effects / foam structures, when generated in treated tissue (treated affected tissue) by drugs containing agents that produce physical effects / foam structures, increase the dispersion rate of the active treatment component into the treated tissue by tens to hundreds of times, thereby helping the treatment active component overcome the protection of the dense structure / high-viscosity fluid-containing structure of the affected tissue, which is a structure that protects the virulence factors / pathogenic entities in the affected tissue. Therefore, until now, there have been no drugs containing [treatment active component + drug that produces a sufficiently strong physical effect] / [active treatment component + drug that produces a sufficiently strong physical effect + drug that produces a foam structure (e.g., peroxide)] for treating affected tissue (e.g., infected tissue / necrotic tissue / fungal infected tissue / affected tissue containing fluids with many toxins / benign tumors / cancerous tumors). [Prior art documents] [Patent Documents]

[0041] [Patent Document 1] U.S. Patent Application Publication No. 2009 / 0030079 Specification [Patent Document 2] U.S. Patent No. 11033579 [Patent Document 3] U.S. Patent Application Publication No. 2007 / 0293466 Specification [Patent Document 4] Chinese Patent Application Publication No. 2006 / 100154378 Specification [Patent Document 5] UK Patent Application Publication No. 0415768 [Overview of the project] [Problems that the invention aims to solve]

[0042] The present invention relates to a drug containing a chelating agent having the ability to retain [Zn ions / other heavy metal ions] for treating the symptoms of diseases caused by pathogenic microorganisms, and for preventing or treating diseases caused by pathogenic microorganisms / diseases caused by toxins and neurotoxins / diseases that weaken the immune system due to chronic diseases or a decrease in polyamine derivatives in the elderly / cancer / several other diseases / several syndromes / affected tissues (e.g., infected tissue / necrotic tissue / tissue containing many toxins / benign tumors / cancerous tumors). [Means for solving the problem]

[0043] In the process of exploring pharmaceuticals for treating the various diseases mentioned in the description of this invention, thanks to the vast number of biological / chemical / physical experiments and clinical trials on various small animals (including mammals such as mice) and the implementation of a series of clinical treatment trials on patients (humans) with numerous different diseases (including Covid-19 disease / disease tissue (including severely infected tissue / cancerous tissue)), the invention has discovered many ways to treat many different diseases / syndromes. In particular, the pharmaceuticals for treating diseases caused by microorganisms of this invention have the effect of rapidly eliminating symptoms, causing microorganisms to lose their ability to bind to host cells, rapidly weakening pathogenic microorganisms, strengthening the host's immune system, and preventing the appearance of post-disease syndromes. The invention has been found to treat affected tissues (e.g., infected tissue / necrotic tissue / fungal tissue / benign tumors / cancerous tumors), and these pharmaceuticals contain agents that produce a strong physical effect in the treated tissue / create a foam structure in the treated tissue. Therefore, these agents cause the active ingredients of the agents to overcome the dense structure / high-viscosity fluid-containing structure of the affected tissue, which is a structure that protects the virulence factors / pathogenic entities within the affected tissue, and the dispersion rate of the active ingredients of the agents in the treated tissue is tens to hundreds of times faster than that of current agents (which do not produce a physical effect / do not produce a sufficiently strong physical effect / do not create a foam structure in the treated tissue). Thanks to this, these agents of the present invention are an effective and outstanding treatment of affected tissue.

[0044] The following are some new fundamental foundations upon which the drug type of the present invention is based for development. -In a water-containing environment of an organism's body / host body (the host is an animal / human), for example in blood / tissue fluid / alveolar fluid / intracellular fluid, when the body is depleted of chelators (see these chelators below) that have the characteristic of capturing [Zn ions / other transition metal ions], Zn ions form complexes with Cu ions / Mg ions / Ca ions / Fe ions / Mn ions / Ni ions / Co ions / Pd ions / Pb ions / Hg ions, etc.], and the complex [Zn ion-Cu ion / Zn ion-Mg ion / Zn ion-Ca ion / Zn ion-Fe ion / Zn-ion-Mn ion / Zn The formation of these complexes generates [Zn-Ni ions / Zn-Co ions / Zn-Pd ions / Zn-Pb ions / Zn-Hg ions, etc.], and the formation of these complexes is analogous to the formation of these complexes in batteries containing electrode pairs [Zn-Cu / Zn-Mg / Zn-Ca / Zn-Fe / Zn-Mn / Zn-Ni / Zn-Co / Zn-Pd / Zn-Pb / Zn-Hg, etc.] (the electrode pair [Zn-other metals] may be in metallic form or in the form of insoluble metal derivatives). The formation of these complexes generates an electric current during their formation and alters the redox properties around these complexes during their formation. The formation of [Zn-Cu ions] complexes can be observed by adding an excess amount of 1% sodium ascorbate solution to a test tube containing a solution of [0.1% CuCl2 + 0.6% ZnCl2 (or more)]. As a result, no metallic Cu suspension will appear. When an excess amount of 1% sodium ascorbate solution is added to a test tube containing 0.1% CuCl2, metallic Cu suspensions will appear. The result is that metallic Cu suspensions will appear. When an excess amount of 1% sodium ascorbate solution is added to a test tube containing a solution of [0.1% CuCl2 + several percent [arginine / lysine / triethylenetetramine / triethylenetetramin glutamic acid / triethylenetetramine diethylenetriamine pentaacetic acid / Mg EDTA / Mg DTPA]], metallic Cu suspensions will not appear.

[0045] -The biological significance of the discovery mentioned above (the discovery of the formation / existence of [Zn ion-other metal ion] complexes in aquatic environments) is very broad. Here, for example, -when a host suffers from a disease caused by pathogenic microorganisms / severely other diseases, chelators are depleted (also known as chelating agents. These chelators are mainly derivatives of polyamines, e.g., derivatives of [histidine / lysine / arginine / agmatine / cadaverine / putrescine / spermidine / spermine, etc.]. These polyamine derivatives are chelators with [Zn ion / other heavy metal ion] scavenging characteristics), and this depletion is because these chelators completely scavenge Zn derivatives released from pathogenic microorganisms and fragments of pathogenic microorganisms, and because these chelators completely scavenge [Fe ions / Cu ions / Zn ions / other heavy metal ions] from host cells / host red blood cell fragments (attacked by pathogenic microorganisms). - In a state where the host body is depleted of these chelators, the Zn ions of these Zn derivatives will bind to metal ions on the structure of peptides (soluble) / proteins (soluble) in the blood / alveolar fluid / tissue fluid, generating Zn-peptide complex suspensions / Zn-protein complex suspensions, causing symptoms of blood viscosity / tissue fluid viscosity / alveolar fluid viscosity. - In a state where the host body is depleted of these chelators, pathogenic microorganisms will readily accumulate Zn ions / other heavy metal ions to satisfy their need for rapid proliferation, leading to a rapid deterioration of the disease state of primary and secondary diseases caused by pathogenic microorganisms. - The "Zn ion-binding pins" on proteins on the surface of pathogenic microorganisms (on spike proteins in viruses) are in a free form (not blocked by chelators with [Zn ion / other transition metal ion] capture features). Therefore, they readily bind to metal ions on metalloproteins on the surface of host cells, attacking / entering the host cells. -Zn ions in Zn derivatives may bind to metal ions on the structure of metalloproteins in host cells / host tissues, potentially causing various symptoms / various neurological symptoms / blood clotting / cytokine storms / respiratory failure / acute respiratory failure (collectively referred to as symptoms).-When the above chelators are not depleted and are present in sufficiently high concentrations in the host blood, they will capture [Zn ions / other metal ions] and help reduce the accumulation of [Zn ions / other heavy metal ions / Zn ion-other heavy metal complexes] in [blood / tissue fluid / alveolar fluid / tissues / nerve tissue / brain tissue], thereby preventing / alleviating symptoms and syndromes caused by the accumulation of [Zn ions / other heavy metal ions / Zn ion-other heavy metal complexes] in [tissues / nerve tissue / brain tissue] that cause post-illness syndromes (e.g., post-Covid syndrome / brain fog syndrome in individuals who have had Covid-19).

[0046] - In a water-containing environment within the body of an organism / host (the host being an animal / human), e.g., blood / tissue fluid / alveolar fluid / intracellular fluid, if the body is depleted of chelators capable of capturing [Zn ions / other transition metal ions] (e.g., the remaining amount of chelators capable of capturing [Zn ions / other transition metal ions] is not significant in the patient's body), Cu ions will bind to [Fe ions on metalloproteins of host cells / red blood cells / alveolar cells], causing these cells to lose their ability to exchange O2 and resulting in symptoms of acute respiratory failure (not caused by lung infection). This condition is extremely dangerous as it can quickly lead to death. Among the bonding forces between Cu ions and other metal ions, the Cu-Fe ion complex is the strongest, allowing for the recognition of the presence of Cu-Fe ion complexes, Cu-Zn ion complexes, Cu-Mg ion complexes, and Cu-Ca ion complexes. The Cu-Fe ion bond is the highest grade of bonding type, and Cu-other metal ion bonds can be recognized through experiments conducted in an aqueous environment (an aqueous environment without chelators that can capture [Zn ions / other transition metal ions] mimics the blood environment / alveolar fluid environment of a host with depletion of these chelators). These experiments were carried out by adding an excess amount of 1% sodium ascorbate solution to test tubes containing: [0.1% CuCl2 + over 0.2% FeCl3], [0.1% CuCl2 + over 0.6% ZnCl2], [0.1% CuCl2 + over 0.63% MgCl2], and [0.1% CuCl2 + over 0.65% CaCl2]. The results showed that no metallic Cu suspension would appear in these test tubes. The experiments helped to identify that when the chelator with [Zn ions / Cu ions / other transition metal ions]-capturing ability is depleted in the patient's body, the patient will suffer acute respiratory failure and easily die. These experiments were carried out by keeping Boraras micros in water containing 0.4 ppm CuCl2, which resulted in the fish dying after several hours.If Boraras microstratus fish are kept in water containing [0.4 ppm CuCl2 + several ppm to over 10 ppm of lysine phosphate / arginine phosphate / magnesium ethylenediaminetetraacetate (Mg EDTA) / magnesium diethylenetriaminepentaacetate (Mg ethylenediaminetetraacetate, Mg DTPA) / calcium ethylenediaminetetraacetate (Ca ethylenediaminetetraacetate, Ca EDTA) / calcium diethylenetriaminepentaacetate (Ca DTPA) / triethylenetetraminediethylenetriaminepentaacetate], the fish will not die after several weeks.

[0047] - Experiments help identify the active ingredients used as components of the present invention's chelator agents that are not toxic to host cells (the host is an animal / human) at the host blood concentrations required for disease treatment (type-dependent). This concentration in the host's blood is required for disease treatment. Here, the safety concentration threshold is extremely high for polyamine aminopolycarboxylate / Mg aminopolycarboxylate, very high for Ca aminopolycarboxylate, and average safety level for Cu aminopolycarboxylate (however, when Cu aminopolycarboxylate is combined with other chelators, the safety threshold for Cu aminopolycarboxylate will rise to an extremely high level). These safety thresholds can be determined experimentally, as follows: - When Boraras microscos fish are kept in water containing [800 ppm EDTA Cu / 3000 ppm EDTA Mg / 12000 ppm EDTA Ca], the result is that the fish will not die after 10 days. -If Boraras microsus fish are kept in water containing [800 ppm EDTA Na], the fish will die within 24 hours (because EDTA Na nonselectively captures metal ions, including metal ions such as Fe ions that help exchange O2 in the fish's gills, which will cause acute respiratory failure in the fish, whereas polyamine derivatives / EDTA Cu / EDTA Mg / EDTA Ca will capture Fe ions weakly (not as strongly, and therefore will not cause acute respiratory failure in the fish)). The biological significance of these findings is as follows: -Cu chelate / Mg chelate / Ca chelate are not toxic to animal cells (the bodies of mollusks / arthropods are rich in Cu chelate / Cu ligands, which are Cu-histidine complexes, and humans also commonly eat foods rich in Cu chelate / Cu ligands from mollusks / arthropods). - Depletion of derivatives with Cu ion-scavenging properties in the body of patients with diseases caused by pathogenic microorganisms will cause acute respiratory failure symptoms as described above. This condition is extremely dangerous and can easily lead to rapid death. - Emergency administration to the body of patients with acute respiratory failure symptoms from diseases caused by pathogenic microorganisms (especially Covid-19).The drug of the present invention contains a chelator (also called a chelator drug) (for example, EDTA Mg / DTPA Mg / EDTA Ca / DTPA Ca / triethylenetetraminediethylenetriaminepentaacetic acid) having [Cu ion / Zn ion / other heavy metal ion] scavenging properties in order to rapidly save patients from death due to acute respiratory failure symptoms.

[0048] - Pathogenic microorganisms are rapidly growing organisms (e.g., organic matter-degrading microorganisms / pathogenic microorganisms / pathogenic microorganism syncytium / cancer cells / cancer syncytium / cancerous tissues, etc.). Therefore, they have a high demand for Zn and other transition metals. The proteins of pathogenic microorganisms are rich in cysteine. This helps these proteins accumulate Zn ions / other transition metal ions, making their proteins (especially those on their surface) rich in Zn / other transition metals. When a host (animal / human) suffers from a disease caused by pathogenic microorganisms, there may be three stages related to the following symptoms: - The first stage is when pathogenic microorganisms and their fragments release [Zn derivatives / other transition metal derivatives / Zn-other heavy metal complex derivatives / Zn-other heavy metal-rich peptides and proteins (also called [Zn / other transition metal]-rich products from pathogenic microorganisms, and toxins / neurotoxins, which are also called [Zn / other transition metal]-rich products from pathogenic microorganisms) into the [host blood / tissue fluid / alveolar fluid]. In this stage, the host body still has an abundance of chelators with [Zn / other transition metal] scavenging properties (excluding those with weakened immune systems / elderly individuals), and therefore, the [Zn / other transition metal]-rich products present in the host body that scavenge [Zn ions / other heavy metal ions] from pathogenic microorganisms (natural chelators present in the host body are polyamine derivatives, e.g., histidine / lysine / arginine / cadaverine / putrescine / spermidine / spermine derivatives) prevent [Zn / other transition metal]-rich products from pathogenic microorganisms from binding to the host's metalloproteins. Consequently, symptoms rarely appear during this stage. This stage is characterized by a significant decrease in the amount of [Zn / other transition metal] scavenging properties in the patient's body that retain the ability to scavenge [Zn ions / other transition metal ions], leading to a period where the patient's body is depleted of active [Zn / other transition metal] scavenging properties.The second stage is characterized by the depletion of the aforementioned chelators in the blood, tissue fluid, and alveolar fluid due to the capture of Zn-rich products and other transition metal-rich products from pathogenic microorganisms. In this state of chelator depletion, Zn-rich products and other transition metal-rich products from pathogenic microorganisms, as well as the pathogenic microorganisms themselves, readily bind to host metalloproteins, causing symptoms / toxicity in host cells and tissues, host nerve tissue, and host brain tissue, leading to disease in the host and post-illness syndromes in the host (as seen in some diseases such as post-Covid syndrome). Products rich in [Zn / other transition metals] from pathogenic microorganisms, when bound to host metalloproteins, can cause various symptoms (e.g., fatigue, fever, rash, runny nose, conjunctivitis, diarrhea, mucus thickening, etc.), various neurological symptoms (e.g., loss of taste, loss of smell, loss of appetite, sore throat, muscle pain, joint pain, headache, etc.), blood coagulation, increased viscosity of [blood / tissue fluid / alveolar fluid], cytokine storms, and respiratory distress (collectively referred to as symptoms). In severe cases, these symptoms may lead to host death. Furthermore, the abundance of [Zn / other transition metals]-rich products in the patient's body also provides a rich source of [Zn / other heavy metals] for secondary microorganisms to rapidly proliferate, leading to a rapid worsening of secondary diseases. In addition, the abundance of the aforementioned Zn derivatives / Zn-other heavy metal complex derivatives also leads to the accumulation of Zn ions / Zn-other heavy metal ion complexes in tissues / nerve tissue / brain tissue, resulting in post-illness syndromes (for example, post-COVID syndrome in individuals who have had COVID-19, where their bodies experience prolonged depletion of the aforementioned chelators).

[0049] - Introduction experiment. Diluted Zn derivatives were brought into contact with open wounds on animal skin (the animals used were marine worms / Sipunculids (the marine animals were placed in a box and the material was moistened with seawater for use as fishing bait. These animals have the ability to survive in the air for extended periods in the environment in which they are contained) / mammals, resulting in a rapid increase in infection of the open wounds). These infected open wounds were almost impossible to heal with antibiotics and could only be healed by a chelator with [Zn / other heavy metal] scavenging properties. The significance of these experiments lies in helping to identify that when patients suffer from illnesses caused by primary microorganisms (e.g., the SARS-Covid-2 virus that causes Covid-19), Zn derivatives / Zn-rich peptides are released from SARS-Covid-2 and SARS-Covid-2 fragments, strongly promoting the growth of secondary microorganisms (secondary pathogenic microorganisms) that cause infection, and serving as a source of Zn that leads to rapidly worsening secondary illnesses (e.g., lung infections / fungal infections). This helps identify secondary illnesses associated with primary illnesses such as Covid-19 caused by increased concentrations of Zn derivatives / Zn-rich peptides in the patient's blood / tissue fluid / alveolar fluid, which makes treatment of the secondary illness difficult. These outbreaks (e.g., severe lung fungal infections / infections) are extremely difficult to cure and require treatment with the chelating agents of the present invention for rapid recovery.

[0050] - Experiments in which microorganisms that decompose organic matter are cultured in a controlled liquid medium that does not contain substances that promote the growth of microorganisms that decompose organic matter (e.g., without the addition of [ZnCl2 / FeCl3 / CuCl2 / sodium citrate / sodium succinate / sodium malate / sodium gallate / sodium tannate / boron]), and experiments in which microorganisms that decompose organic matter are cultured in liquid mediums to which each of the substances [ZnCl2 / FeCl3 / CuCl2 / sodium citrate / sodium succinate / sodium malate / sodium gallate / sodium tannate] is added at different concentrations. The above culture medium contains [12 ppm ZnCl2 / [6 ppm ZnCl2 + 2 ppm CuCl2 + 12 ppm FeCl3] / 80 ppm sodium citrate / 80 ppm sodium succinate / 80 ppm sodium malate / 5 ppm sodium gallate / 30 ppm tannic acid], which results in strong growth of microorganisms that decompose organic matter (including bacteria / fungi). Furthermore, when Cu EDTA / Mg EDTA / Ca EDTA / triethylenetetraminediethylenetriaminepentaacetic acid are added to the above environment at the same concentrations of 150 ppm / 400 ppm / 700 ppm / 100 ppm, the growth of microorganisms that decompose organic matter is strongly inhibited. However, when bactrim / ampicillin are added to the above environment at concentrations of 20 ppm / 10 ppm, respectively, the growth of microorganisms that decompose organic matter will only be very slightly inhibited during the first 36 hours. The significance of these experiments is as follows.To help identify substances that promote the growth of microorganisms (including pathogenic microorganisms already present in the patient's body, thanks to experiments testing these substances on open wounds in animal skin), and to avoid exacerbating secondary diseases and worsening symptoms that can be fatal when high doses of Zn supplements are used when a patient has a disease caused by pathogenic microorganisms, it is necessary to restrict foods / beverages / supplements rich in [Zn / citric acid / succinic acid / malic acid / gallic acid / tannic acid], in particular, to avoid using Zn supplement tablets during the disease, and to use Mg aminopolycarboxylate / Ca aminopoly as a good raw material for making chelating agents to treat diseases caused by pathogenic microorganisms. The purpose is to help identify polycarboxylates / polyamine aminopolycarboxylates, which are agents that help partially replace antibiotics / help completely replace antibiotics (to completely replace antibiotics (such as polyamine aminopolycarboxylate salts made from triethylenetetramine (TETA) / tetraethylenepentamine (TEPA) / pentaethylenehexamine (PEHA) / branched poly(ethyleneimine) (branched PEI) and diethylenetriaminepentaacetic acid (DTPA), or salts made from branched TETA / TEPA / PEHA / PEI with a sulfur-functional acid on the molecule, or chelator combinations containing Cu aminopolycarboxylate)).

[0051] - In a state of depletion of a chelator with [Zn ion / other heavy metal ion] scavenging characteristics, a suspension composed of Zn-blood complexes will appear in the blood. Very low concentrations of Zn derivatives (calculated as less than 0.7 to 1.5 ppm as Zn) are sufficient to form Zn-blood complex suspensions, and a chelator with [Zn ion / other heavy metal ion] scavenging characteristics can dissolve the Zn-blood complex suspensions (at neutral to alkaline pH). It can be recognized that Zn-blood complex suspensions are generated by the following experiment: - Gradually add a solution containing 0.01% blood (this 0.01% blood solution is mixed from [animal / human] sample blood and water. The sample blood contains 6% NaCl to help prevent the sample blood from coagulating before use in the experiment. The purpose of using this solution containing a very small amount of blood is to avoid the influence of polyamine derivatives present in the blood on the experimental results, because the blood of a healthy host is rich in polyamine derivatives), as well as 0.001% ZnCl2, and shake well. The results show that Zn-blood suspensions begin to appear when the ZnCl2 concentration exceeds 1.5 ppm. These suspensions appear abundantly when the ZnCl2 concentration reaches 2 ppm. Gradually add a 2 ppm ZnCl2 solution [0.1% arginine phosphate / 0.1% arginine glutamic acid / 0.01% EDTA Mg / 0.01% triethylenetetramine diethylenetriaminepentaacetic acid] to the test tube containing the Zn-blood complex suspension until the suspension is completely dissolved and the solution is clear. This test shows that the amount of [EDTA Mg / triethylenetetramin gluconic acid / triethylenetetramine diethylenetriaminepentaacetic acid / tetraethylenepentamine diethylenetriaminepentaacetic acid / pentaethylenehexamine diethylenetriaminepentaacetic acid / branched polyethyleneimine diethylenetriaminepentaacetic acid] (these are synthetic polyamine derivatives) required to completely dissolve the Zn-blood complex suspension is tens to hundreds of times lower than the amount of lysine phosphate / lysine chloride / arginine phosphate / arginine chloride (these are natural polyamine derivatives).The significance of these studies lies in the fact that when a host suffers from a disease caused by pathogenic microorganisms and reaches a stage where the host's body is depleted of chelators with [Zn ion / other heavy metal ion]-capturing properties, very low concentrations of [Zn derivatives released from pathogenic microorganisms and fragments of pathogenic microorganisms] (calculated as only slightly more than 1.0 ppm as Zn) in the blood are sufficient to create Zn-blood complex suspensions. This means that when the aforementioned chelators are depleted and the concentration of Zn derivatives from pathogenic microorganisms increases, a range of symptoms will occur even when the increased concentration of Zn derivatives in the host's blood is very low. When symptoms appear very severely, the introduction of a small amount of chelator with [Zn ion / other heavy metal ion]-capturing properties into the host's body will dissolve the Zn-blood complex suspensions, and most of the symptoms will rapidly disappear. The above experiments also help to understand that the effects of the chelators of the present invention (the active ingredients are chelators, and therefore they are simply called chelator drugs) including the effect of eliminating symptoms / helping the host body recover / preventing the onset of syndrome far exceed the effects of natural chelators present in the host body (the host is an animal / human). A clinical trial treating Covid-19 with the agent of the present invention containing [1.4g EDTA Mg / 0.8g triethylenetetraminediethylenetriaminepentaacetic acid] showed the following: Most symptoms significantly improved 4 hours after the first dose. After 48 hours, the remaining symptoms were no longer significant. After several days, the patient was cured. Post-Covid syndrome did not appear after the treatment period (including 7 days of treatment and receiving a 1 / 2 treatment dose for 8 days to prevent post-Covid syndrome).

[0052] - Active ingredient polyamine aminopolycarboxylate, for example, polyamines where the polyamine is triethylenetetramine / tetraethylenepentamine / pentaethylenehexamine / branched polyethyleneimine, and ethylenediaminetetraacetic acid (EDTA) / diethylenetriaminepentaacetic acid (DTPA) / triethylenetetramine-N,N,N',N'',N''',N'''-hexaacetic acid (TTHA) / dibenzothiophene-1,3,6,8-tetracarboxylic acid (DTCA) / ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid ( EGTA) / 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BATPA) / 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) / N,N'-bis(2-hydroxyethyl)ethylenediamine-N,N'-diacetic acid (HEEDA) / 1,4,7,10,13-pentazocyclopentadecane pentaacetic acid (PEPA) / 1,4,7,10,13,16-hexazocyclooctadecane hexaacetic acid (HEHA) / 1,4,8 ,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) / triethylenetetraminepentaacetic acid (TETPA) / 4,5-diphenyl-1,3-oxazole-2-yl)thio](phenyl)acetic acid (DOTPA) / 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (DOTMP) / Ethylenediamine-N,N'-disuccinic acid (EDDS) / 2-Hydroxyethyliminodiacetic acid (HEIDA) / Glutamate diacetic acid (GLDA) / Methylglycine diacetic acid (MGDA) / l-Asparagine Acid N,N-diacetic acid (ASDA) / 1,2-cyclohexylenediaminetetraacetic acid (CDTA) / ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) (EDDHA) / ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) / [2-{4,7-biscarboxymethyl(1,4,7)triazacyclonona-1-yl-ethyl}carbonylmethylamino]acetic acid (NETA) / 1,2-cyclohexylenedinitrilotetraacetic acid (CyDTA) / triethylenetetraaminehexaacetic acid (TTHA) / 1,4,7,Polyamine aminopolycarboxylates, derived from aminopolycarboxylic acids such as 10-tetraaza-cyclododecane-1,4,7-triacetate (DO3A) / 6-amino-6-methylperhydro-1,4-diazepine tetraacetic acid (AAZTA), are chelators that neutralize the toxicity of toxins / neurotoxins (including toxins / neurotoxins produced by pathogenic microorganisms in the patient's body, and external toxins / neurotoxins (e.g., from rodenticides / insecticides / poisonous animal toxins / poisonous plants / poisonous mushrooms / toxins produced by technology) / biological preparations / severe organic and inorganic toxins). The active ingredient triethylenetetraminediethylenetriaminepentaacetic acid and several other polyamine aminopolycarboxylates mentioned above have been used for the clinical treatment of small animals (e.g., Boraras microsus fish / flies and maggots / crickets / earthworms / marine worms / striped worms / chickens / mice). They are contaminated with toxins / neurotoxins, which are the active ingredients in many rodenticides / insecticides / some poisonous plants, etc. All of these studies have achieved results that help prevent experimental animals from dying, even when exposed to doses of these toxins / neurotoxins several to tens of times the minimum amount that would kill them.

[0053] -The following clinical trials using Boraras microsus fish have demonstrated the ability of the active ingredient triethylenetetraminediethylenetriaminepentaacetic acid to neutralize the toxicity of toxins. When fish are kept in water containing [5 ppm nereistoxin + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish will survive for several days (up to several weeks), but when fish are kept in water containing only 5 ppm nereistoxin, the fish will die after 30 minutes. • When fish were kept in water containing [1.25 ppm furcumafen (1 / 4 tablet of rodenticide (0.005% furcumafen) in 1 liter of water) + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days (up to several weeks), but when fish were kept in water containing 1.25 ppm furcumafen, the fish would die after 36 hours. When fish were kept in water containing [0.3 ppm bromadiolon + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 0.3 ppm bromadiolon, the fish died within 12 hours. When fish were kept in water containing [0.2 ppm methylamine avermectin + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 0.2 ppm methylamine avermectin, the fish died within 12 hours. When fish were kept in water containing [2.5 ppm emamectin benzoate + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 2.5 ppm emamectin benzoate, the fish died within a few hours. When fish were kept in water containing [1.0 ppm phenylperazole + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 1.0 ppm phenylperazole, the fish died within a few hours. When fish were kept in water containing [0.2 ppm alpha-cypermethrin + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 0.2 ppm alpha-cypermethrin, the fish died within a few hours. When fish were kept in water containing [0.3 ppm CuCl2 + 20 ppm ZnCl2 + 20 ppm FeCl3], the fish survived for several days, but when fish were kept in water containing [0.3 ppm CuCl2 + 20 ppm ZnCl2], the fish died within a few hours. These experiments help to identify that during the hemorrhagic stage of dengue fever, the patient's fever decreases and they feel better due to an increase in the concentration of Fe derivatives in the blood (from broken red blood cells). When fish were kept in water containing 2000 ppm triethylenetetraminediethylpentaacetic acid / 3000 ppm Mg EDTA / 2000 ppm Cu EDTA / 12000 ppm Ca EDTA / [10000 ppm + 2500 ppm CuCl2], the fish survived for several days, but when fish were kept in water containing 1000 ppm Na2 EDTA / 0.5 ppm CuCl2 / [0.3 ppm CuCl2 + 20 ppm ZnCl2], the fish died within a few hours. These experiments help to identify the toxicity thresholds of the above chelators to host cells (the host is animal / human), and Ca EDTA / Ca EDTA are highly safe and help treat poisoning from extremely high contamination levels of heavy metal derivatives / radioactive metal derivatives.

[0054] -The following clinical experiment using Boraras microsus fish has demonstrated the ability of the active ingredient triethylenetetraminediethylenetriaminepentaacetic acid to inhibit / kill pathogenic microorganisms. A certain amount of Boraras microsus fish (approximately 100g) that had died after 3 days was used. This amount of dead fish was placed in 10 liters of water, and the fish were kept for 2 days so that all the fish in this 10 liters of water would be infected with pathogenic microorganisms from the 100g of fish that had died after 3 days. Then, 1 liter of water containing the above dead fish was added to each large beaker, and each beaker contained approximately 30 live fish. Then, one beaker was used as a control experiment, and the remaining beakers were filled with substances so that each container contained 10 ppm ampicillin / 20 ppm bactrim / 20 ppm ampicillin / 40 ppm bactrim / 100 ppm triethylenetetraminediethylenetriaminepentaacetic acid / 300 Mg EDTA / 600 ppm Ca EDTA / 50 ppm Cu EDTA + 100 ppm triethylenetetraminediethylenetriaminepentaacetic acid / [0.3 ppm ampicillin + 50 ppm triethylenetetraminediethylenetriaminepentaacetic acid] / [0.6 ppm bactrim + 50 ppm triethylenetetraminediethylenetriaminepentaacetic acid]. The result was that after 6 days, in the control experiment beaker / [10 ppm ampicillin / 20 ppm bactrim / 20 ppm ampicillin / 40 ppm bactrim], all the fish in the beakers were dead, and the water in these beakers was cloudy. Six days later, in beakers containing [100 ppm triethylenetetraminediethylenetriaminepentaacetic acid / 300 Mg EDTA / 600 ppm Ca EDTA / 50 ppm Cu EDTA + 100 ppm triethylenetetraminediethylenetriaminepentaacetic acid / [0.3 ppm ampicillin + 50 ppm triethylenetetraminediethylenetriaminepentaacetic acid] / [0.6 ppm bactrim + 50 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish did not die, and the water in these containers was clear.

[0055] -The above results also suggest that when polyamine aminopolycarboxylates are present at very low concentrations in the host [blood / tissue fluid / alveolar fluid] (over 30 ppm for polyamine aminopolycarboxylates made from TEPA / PEHA / branched PEI and DTPA) (over 60 ppm for polyamine aminopolycarboxylates formed from TETA and DTPA), their ability to inhibit / kill pathogenic bacteria far exceeds that of bactrim at a concentration of 10 ppm / ampicillin at a concentration of 20 ppm in the host [blood / tissue fluid / alveolar fluid].

[0056] Specifically, drugs containing the components [polyamine aminopolycarboxylate + antibiotic active ingredient] / [polyamine aminopolycarboxylate + a salt made from polyamine and at least one acid having a sulfur functional group on the molecule] are drugs that kill pathogenic microorganisms very strongly. Therefore, they are outstandingly effective drugs in treating diseases caused by pathogenic microorganisms, and while greatly reducing the dose of the active ingredient of antibiotics / helping to eliminate the need for antibiotics, they also provide the aforementioned set of other benefits (e.g., rapidly reducing symptoms / clearing the body from the accumulation of [Zn ion accumulation / other transition metal ions] / relieving pain and inflammation, etc.).

[0057] - The experiment helps identify Zn-rich derivatives (mimicking Zn-rich products from pathogenic microorganisms) as factors that cause symptoms of taste loss and various other symptoms (e.g., in Covid-19 / influenza / diseases caused by pathogenic microorganisms). - The symptom of taste loss caused by Zn derivatives can be identified by chewing a 15 mg Zn gluconate tablet, holding it in the mouth, spitting it out after 120 seconds, and then tasting a solution [15% sucrose / sweet aspartame / sweet sucralose], resulting in a complete loss of sweetness on the tongue. Then, hold a solution [5% arginine glutamate / 0.5% triethylenetetramethyl glutamate] in the mouth for 10 seconds and taste the solution [15% sucrose / sweet aspartame / sweet sucralose] again. The result is a complete recovery of sweetness on the tongue.

[0058] - The experiment helps identify Zn-rich derivatives (mimicking Zn-rich products from pathogenic microorganisms) as factors that cause symptoms (e.g., scratchy throat / sore throat / cough / runny nose / body aches / low-grade fever / headache, etc. are similar to these symptoms of diseases caused by pathogenic microorganisms (e.g., influenza / viral fever / Covid-19, etc.)). The experiment (this experiment is for experts only, because it causes unpleasant symptoms for several hours to over 24 hours, and triethylenetetramine derivatives should be available for oral ingestion to quickly alleviate these symptoms) involves holding 2 ml of 0.4% ZnCl2 solution (which contains about 80 mg of ZnCl2) in the mouth for 120 seconds. Then, a small amount of this solution is swallowed and then spit out. The result is that the above symptoms appear several minutes to several hours later. Then, slowly drink several ml of the solution [10% triethylenetetramine glutamate / 10% triethylenetetramine ascorbic acid]. The result is that the above symptoms will gradually disappear after a few hours. Finally, the headache symptoms will disappear.

[0059] -The experiment helps identify factors that cause symptoms of increased blood viscosity / blood clotting / dengue disease bleeding, based on the results of the following experiments. -Add 1.4 ml of 0.1% ZnCl2 solution to a test tube containing 100 ml of 0.9% NaCl solution and 1% blood (mammalian blood / human blood; NaCl is added to this blood sequentially. NaCl has 6% to prevent the blood from clotting before dilution with water). The result is that a suspension containing Zn-blood complex components will begin to appear (when more 0.1% ZnCl2 solution is added to the test tube, the density of the suspension will increase accordingly). -Add 6 ml of 0.1% FeCl3 solution to the test tube containing the above suspension. The result is that the suspension will dissolve completely. The solution will become clear. -Add 4 ml of neutral [NaH2PO4+Na2HPO4] solution to the clear solution. The result is that the suspension will reappear. -Repeat the first experiment to obtain a test tube containing a suspension containing Zn-blood complex components. Next, add 2 ml of 10% neutral arginine phosphate solution (3 parts arginine: 1 part H3PO4 (type 85% H3PO4)) to this test tube. The result is that the suspension dissolves completely and the solution becomes clear. - Repeat the first experiment to obtain a test tube containing a suspension with Zn-blood complex components. Next, add 1.0 ml of 10% neutral glutamate arginine solution (1 part glutamate: 1.36 parts arginine). The result is that the suspension dissolves completely and the solution becomes clear. - Repeat the first experiment to obtain a test tube containing a suspension with Zn-blood complex components. Next, add 0.7 ml of ascorbic acid arginine (1 part arginine: 1 part ascorbic acid) to this test tube. The result is that the suspension dissolves completely and the solution becomes clear. - Repeat the first experiment to obtain a test tube containing a suspension with Zn-blood complex components. Next, add 2 ml of 0.1% EDTA Mg solution to this test tube. The result is that the suspension dissolves completely and the solution becomes clear. - Repeat the first experiment to obtain a test tube containing a suspension with Zn-blood complex components. Then, add 1.2 ml of triethylenetetraminediethylenetriaminepentaacetic acid to this test tube. The result is that the suspension dissolves completely and the solution becomes clear.The results described above and those from other experiments demonstrate the ability of the chelators used as active ingredients in the chelator agents of the present invention to dissolve suspensions containing Zn-blood complex components. For example, Mg EDTA / Ca EDTA / Mg DTPA / Ca DTPA / [TETA / TEPA / PEHA / salts formed from branched PEI and DTPA] are 70 to 200 times more potent than lysine phosphate / lysine chloride / arginine phosphate / arginine chloride. These help to identify that the agents of the present invention have the ability to [alleviate symptoms / weaken pathogenic microorganisms / strengthen the immune system], far exceeding the ability of natural chelators (mainly natural polyamine derivatives) present in the host body. Thanks to this, the agents of the present invention have the ability to help save lives from severe / critical cases of diseases caused by pathogenic microorganisms, including severe / critical cases of dangerous diseases with high / very high mortality rates (e.g., Covid-19 / avian influenza).

[0060] - An experiment measuring the voltage obtained from an electrode pair [metal Zn-metal Cu] applied to the skin surrounding [inflammable / infected tissue] (each electrode surface has a fabric layer that captures a gel solution + polarization factor (e.g., NaCl)). A control measurement is performed by applying this electrode pair to the skin of healthy tissue. The results show that the voltage obtained from [inflammable / infected tissue] is considerably higher than the voltage obtained from healthy tissue. The voltage obtained from [inflammable / infected tissue] is high because it is depleted of chelators that have the characteristic of capturing [Zn ions / Cu ions / Fe ions / other heavy metal ions]. Metalloproteins in [tissue / nerve tissue / brain tissue] have [Zn-Cu / Zn-other metal / Cu-other metal] electrode pairs (these electrode pairs are in the form of insoluble metal derivatives). In the state of depletion of the above chelators in the above tissues (and the host body), the voltage of the above electrode pairs increases, and this increase will cause symptoms such as inflammation / tissue pain / muscle pain / headache. This voltage increase can be observed by placing an electrode pair [metallic Zn-metallic Cu] connected to a voltage measuring device (measuring range of 0 volts to 2 volts) into a test tube (the test tube has a diameter of more than 20 mm). This test tube contains a solution [0.9% NaCl + 0.2 ppm CuCl2 + 0.4 ppm ZnCl2 + 0.6 FeCl3 + sufficient 100% water]. A solution of 0.1% arginine phosphate (neutral) / 0.1% arginine glutamic acid / 0.01% EDTA Mg / 0.01% triethylenetetramine glutamic acid / 0.01% triethylenetetramine diethylenetriamine pentaacetic acid] is gradually added to this test tube until the resulting voltage drops significantly. The result is that the amount of arginine phosphate / arginine glutamic acid used to significantly reduce the voltage is several tens of times greater than the amount of [EDTA Mg / triethylenetetramine glutamic acid / triethylenetetramine diethylenetriamine pentaacetic acid] used to significantly reduce the voltage.The biological significance of these findings is that when the patient's body (a body suffering from a disease caused by pathogenic microorganisms) / affected tissue (infected tissue / inflammatory tissue) is depleted of the above-mentioned chelators, the patient's body / affected tissue / painful tissue / inflammatory tissue will reduce pain / inflammation in the patient's body / affected tissue after the above-mentioned chelators become present in the patient's body / affected tissue, thanks to the introduction of the agents of the present invention containing the above-mentioned chelators into the patient's body / affected tissue. The mechanism by which the above-mentioned chelators reduce inflammation / pain is that they capture (i.e., inactivate) metal ions such as Cu ions / Zn ions / Fe ions / other metal ions, which are factors involved in the generation of high-voltage currents (in the state of chelator depletion) in metalloprotein electrode pairs of tissue / nerve tissue / brain tissue, thereby helping to reduce pain / inflammation.

[0061] - An experiment was conducted to measure the voltage obtained from electrode pairs [metal Zn-metal Cu] applied to the skin surrounding [inflammable tissue / infected tissue] injected with the above-mentioned chelator / peroxide / high-concentration glycerol solution (the surface of each electrode had a fabric layer that captured a gel solution + polarization factor (e.g., NaCl)). The voltage obtained from these tissues decreased significantly after injection of the above-mentioned solution. The biological significance of the above findings related to voltage is that pain / inflammation occurs in the patient's body / affected tissue when the patient's body / affected tissue (infected tissue / inflammable tissue) is depleted of the above-mentioned chelator. Then, thanks to the introduction of the agent of the present invention containing [peroxide / glycerol with high-concentration glycerol / [glycerol with high-concentration glycerol + peroxide]] into the patient's body / affected tissue, pain / inflammation in the patient's body / affected tissue will be reduced after the above-mentioned solution of [peroxide / high-concentration glycerol / [glycerol with high-concentration glycerol + peroxide]] is present in the patient's body / affected tissue. The mechanism by which high concentrations of glycerol reduce inflammation / pain in affected tissue is that glycerol reduces the polarity of the affected tissue, which causes a high voltage current at the electrode pair of metalloproteins in the affected tissue (in the state of chelator depletion described above), thereby helping to reduce pain / inflammation. The mechanism by which peroxides reduce inflammation / pain in affected tissue (e.g., infected tissue / necrotic tissue / cancerous tissue / tissue containing highly polar fluids, etc.) is that peroxides oxidize the metal ion complex crosslinks (e.g., Zn-Fe complex / Cu-Fe complex / Zn-Cu-Fe complex crosslinks, etc.) on the metalloproteins of pathogens (e.g., pathogenic microorganisms / cancer cells / toxins), causing these crosslinks to break down and be converted into insoluble metal oxides, thereby lowering the voltage at the electrode pair in the affected tissue and helping to reduce pain / inflammation.Another important biological significance of the drug of the present invention containing [high concentration glycerol + peroxide] / [high concentration glycerol + peroxide + chelator] is its ability to treat affected tissue (e.g., bacterial-infected tissue / fungal-infected tissue / necrotic tissue / dark-colored benign tumors / cancerous tumors (cancerous tissue) / affected tissue containing highly polarized fluid tissue, etc.) with very high treatment efficacy and very short treatment time (less than 24 hours to several days (several days for large-volume cancerous tissue) by sequentially injecting small doses into different locations in large-volume cancerous tissue). Thanks to this, pathogens [[pathogenic microorganisms / cancer cells rich in H2O2 decomposition catalysts] / toxins also rich in H2O2 decomposition catalysts] are rapidly killed / destroyed, while healthy cells remain safe because they are poor in H2O2 decomposition catalysts. This is particularly important in the science of treating affected tissue, especially in the science of treating cancerous tissue. This is because the drug contains [high concentrations of glycerol + peroxide] / [high concentrations of glycerol + peroxide + artificial chelate], which helps to kill all cancer cells in cancerous tissue in a very short time (less than 24 hours to several days; several days in large cancerous tissues). This is of particular importance in the science of treating affected tissue, especially in the science of treating cancerous tissue. This is because the drug contains [high concentrations of glycerol + peroxide] / [high concentrations of glycerol + peroxide + chelator], which helps to kill all cancer cells in cancerous tissue in a very short time (less than 24 hours to several days; several days in large cancerous tissues).

[0062] From the above discoveries, the present invention has identified a series of new fundamental biological foundations in the biological world. Based on these fundamental biological foundations, the present invention has developed a type of drug in which the active ingredient is a chelator (referred to as a chelator drug) having [Zn ion / other transition metal ion] scavenging characteristics, for treating the above symptoms / diseases / syndromes. The chelator drugs of the present invention act by a mechanism completely different from that of existing drugs for treating the above symptoms / diseases / syndromes. The chelator drugs of the present invention aim to precisely attack virulence factors / pathogenic entities. Therefore, the chelator drugs of the present invention have outstanding efficacy in disease prevention / disease treatment, and thanks to this, the drugs have the ability to save lives in severe / critical cases of most diseases caused by pathogenic microorganisms, including dangerous diseases with high / very high mortality rates. In particular, the chelator drugs of the present invention are highly effective in treating cases of respiratory distress / respiratory failure / acute respiratory failure in diseases caused by microorganisms. The chelator of the chelator drugs of the present invention has the following effects and the following mechanism of action. Symptoms / neurological symptoms in diseases caused by pathogenic microorganisms and some other diseases. • Blood viscosity / tissue fluid viscosity / alveolar fluid viscosity / blood coagulation in diseases caused by microorganisms and in the treatment of anaphylactic shock caused by drug injection / vaccination / infusion, and treatment of anaphylactic shock cases caused by drug injection / vaccination / infusion. • Shortness of breath / respiratory failure / acute respiratory failure in diseases caused by microorganisms, and shortness of breath / respiratory failure / acute respiratory failure after disease. • Cytokine storm. Most diseases caused by microorganisms, including dangerous diseases with high (including Covid-19) / very high mortality rates. • Severe cases of disease caused by pathogenic microorganisms (including severe cases of dangerous diseases with a high / very high mortality rate, including Covid-19). • An infectious disease that can spread easily. • Chronic diseases in the elderly / Weakened immune system caused by depletion of polyamine derivatives. • Prevents metastasis in patients with stage 3 and 4 cancer. The affected tissue can be bacterially infected tissue, necrotic tissue, fungalally infected tissue, tissue containing fluid with many toxins (tissue with proliferating cells), benign tumors, or cancerous tumors (tissue with cancerous cells). • Diseases caused by external toxins / external neurotoxins. • Several other different disease types. Infectious diseases spread easily. By using the active ingredient of chelators (mainly calcium aminopolycarboxylate), we create environmental treatment products that help prevent the spread of infectious diseases. Diseases caused by pathogenic microorganisms present in products outside the host body. These products are created for handling / storing by the use of active ingredient chelators (primarily polyamine aminopolycarboxylates). The immune system is easily weakened when a host is infected with a disease caused by microorganisms. By using the active ingredients of chelators, they can be introduced into products such as beverages, processed foods, spices, cooked foods, vitamin supplements, and various pharmaceuticals.

[0063] Based on discoveries concerning chelators and the physical effects / novel chemical bonding in biology, the present invention has developed a drug type for treating affected tissue that contains a chelator and an agent that produces a strong physical effect in the affected tissue (referred to as a chelator-strong physical effect drug type). The active ingredient is a chelator with [[Zn ion / other transition metal ion] scavenging characteristics + an agent that produces a strong physical effect in the affected tissue (e.g., high concentration glycerol) + low water content], which treats affected tissue (e.g., bacterial infected tissue / necrotic tissue / fungal infected tissue / affected tissue containing fluids with many toxins / benign tumors / cancerous tumors). This drug type works by a mechanism that causes the affected tissue, which has a dense structure / contains a highly viscous fluid, to lose its ability to protect virulence factors / pathogenic entities. These structures make the rate at which the treatment component disperses in the treated tissue very slow, making the treatment of these affected tissues difficult (especially in large-volume affected tissues). This drug type produces a series of physical effects in the treated tissue. These offer a range of benefits for the treatment of the affected tissue, and these benefits are as follows: • Greatly increases the rate of drug dispersion in the affected tissue. • Temporarily replaces a large amount of water in the affected tissue with glycerol. This strongly inhibits the activity of pathogenic microorganisms in tissue infected with pathogenic microorganisms / cancer cells in cancerous tissue, but does not cause harm to the host tissue / host cells. It softens tissue, promotes tissue healing, and helps reduce pain caused by dehydration of open wounds during tissue healing. • Recirculate the affected tissue back into the bloodstream (which contains many white blood cells / antibodies). • Reduces the voltage between electrode pairs in the affected tissue / nerve tissue, thereby reducing inflammation / pain. • Weakens pathogenic microorganisms / cancer cells. • Completely stops the activity of pathogenic microorganisms / cancer cells. • Neutralizes the toxicity of toxins and neurotoxins in the treated tissue. • Inactivates sources of Zn / other heavy metals that pathogenic microorganisms / cancer cells require for rapid proliferation. • Many other benefits, etc.

[0064] The above-mentioned chelator-strong physical effect drug type produces a series of strong physical effects in the treated tissue, resulting in the series of benefits described above. Therefore, this drug type is very effective in treating affected tissue and helps to obtain a short treatment time. However, current drugs do not contain chelators with strong [Zn ion / other transition metal ion] scavenging characteristics and do not contain drugs that produce strong physical effects in the treated tissue. Therefore, current drugs for treating affected tissue have many difficulties in treating the affected tissue (especially in affected tissues with large volumes).

[0065] The discoveries concerning chelators and the physical effects in biology / the discoveries concerning the novel chemical bonding described above, along with the discovery of other strong physical effects / physical effects that create foam structures in treated tissue, bring about a series of other significant benefits in the treatment of affected tissue. From these discoveries, the present invention has developed a type of drug that not only produces a series of effects and strong beneficial physical effects in treated tissue as described above, but also imparts foam structures to the treated tissue, helping to cause virulence factors / pathogenic entities to reside within thin walls created between microbubbles, and helping to produce many other beneficial physical effects (for example, continuous changes in bubble pressure help increase the permeation of active ingredients to virulence factors / pathogenic entities located within thin walls). The drug contains components including [a chelator with strong [Zn ion / other transition metal ion] scavenging properties + an agent that accelerates the rate of permeation into the treated tissue (e.g., high concentration glycerol) + an agent that creates a foam structure in the treated tissue, which is a peroxide + a low concentration of water] (referred to as a chelator-foam-strong physical effect agent for treating affected tissue (e.g., bacterial infected tissue / necrotic tissue / fungal infected tissue / disease tissue containing fluids with many toxins / benign tumors / cancerous tumors)]. Chelater-foam-strong physical effect agents have the same effects as the chelator-strong physical effect agents described above. At the same time, they have the following additional effects: • It kills microorganisms / cancer cells extremely rapidly. This is because it oxidizes Zn-Fe crosslinks / Zn-Cu-Fe crosslinks / other Zn-heavy metal crosslinks, converting them into metal oxides, causing these crosslinks to break down, which leads to the rapid death of microorganisms / cancer cells (healthy host cells remain safe because the amount of H2O2 catalyst in healthy host cells is considerably lower than the amount of H2O2 catalyst in pathogenic microorganisms / cancer cells).

[0066] • Rapidly oxidizes toxins in the affected tissue and rapidly eliminates their toxicity. It creates a foam structure in the affected tissue so that virulence factors / pathogenic entities reside within thin walls formed by microbubbles, greatly increasing the dispersion rate of the active treatment component in the affected tissue. This ensures very thorough contact between virulence factors / pathogenic entities and the active treatment component in the treated tissue, helping to kill pathogenic microorganisms / cancer cells very rapidly. It also helps to rapidly oxidize toxins in the affected tissue, causing these toxins to rapidly lose their toxicity. This creates a series of beneficial mechanical effects for treatment (e.g., increasing and decreasing the volume of bubbles; bubbles push each other further away; increasing drug permeability of the bubble walls / increasing contact between the drug and pathogens and toxins in tissue disease, etc.), helping to effectively treat the affected tissue in a much shorter treatment time and helping to reduce disease recurrence. • Causes virulence factors / pathogenic entities to reside within thin walls created by microbubbles (chelator-form - strong physical effect drug), thereby accelerating and greatly increasing the dispersion of the drug-active component in the affected tissue, causing the drug-active component to come into complete contact with all virulence factors / pathogenic entities in the treated tissue. • The continuous changes in pressure of the bubbles that create the thin wall cause the drug-active ingredient to strongly penetrate the virulence factors / pathogenic entities within the thin wall. As a result, the amount of drug-active ingredient that enters the virulence factors / pathogenic entities within the thin wall increases, rapidly killing these pathogenic entities within the thin wall. [Modes for carrying out the invention]

[0067] The present invention provides a chelator drug having an active ingredient (referred to as a chelator drug) which is a chelator having strong [Zn ion / other transition metal ion] scavenging characteristics, where these chelators having strong [Zn ion / other transition metal ion] scavenging characteristics can scavenge more [Zn ions / other transition metal ions]. These chelators are more effective in [relieving symptoms of diseases caused by microorganisms / relieving post-disease syndromes / treating diseases caused by pathogenic microorganisms / treating toxins and neurotoxins that cause disease / treating cancer / treating weakened immune systems in chronic diseases (e.g., HIV / tuberculosis / chronic lung infection / chronic diseases of other diseases caused by pathogenic microorganisms / cancer stages 3 and 4) / treating weakened immune systems in the elderly / treating syndromes in the elderly / treating secondary diseases caused by secondary pathogenic microorganisms, etc.], and the present invention provides a chelator drug having the following typical strong [Zn ion / other transition metal ion] scavenging characteristics (please understand that the abbreviations below are abbreviations for the substances mentioned above). -Polyamine aminopolycarboxylates consist of a polyamine where the polyamine is triethylenetetramine (TETA) / tetraethylenepentamine (TEPA) / pentaethylenehexamine (PEHA) / branched polyethyleneimine (branched PEI) and an aminopolycarboxylic acid where the aminopolycarboxylic acid is ethylenediaminetetraacetic acid (EDTA) / diethylenetriaminepentaacetic acid (DTPA) / triethylenetetramine-N,N,N',N'',N''',N'''-hexaacetic acid (TTHA) / dibenzothiophene-1,3,6,8-tetracarboxylic acid (DTCA) / ethylene Glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) / 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BATPA) / 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) / N,N'-bis(2-hydroxyethyl)ethylenediamine-N,N'-diacetic acid (HEEDA) / 1,4,7,10,13-pentazocyclopentadecane pentaacetic acid (PEPA) / 1, 4,7,10,13,16-Hexazocyclooctadecane hexaacetic acid (HEHA) / 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) / Triethylenetetramine pentaacetic acid (TETPA) / 4,5-Diphenyl-1,3-Oxazole-2-yl)thio](phenyl)acetic acid (DOTPA) / 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetramethylenephosphonic acid (DOTMP) / Ethylenediamine-N,N'-disuccinic acid (EDDS) / 2-Hydroxyethyliminodiacetic acid ( HEIDA) / Glutamate diacetic acid (GLDA) / Methylglycine diacetic acid (MGDA) / l-Aspartate N,N-diacetic acid (ASDA) / 1,2-Cyclohexylenediaminetetraacetic acid (CDTA) / Ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) (EDDHA) / Ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) / [2-{4,7-biscarboxymethyl(1,4,7)triazacinona-1-yl-ethyl}carbonylmethylamino]acetic acid (NETA) / 1,It is made from a polyamine consisting of 2-cyclohexylenedinitrilotetraacetic acid (CyDTA), triethylenetetraamine hexaacetic acid (TTHA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DO3A), and 6-amino-6-methylperhydro-1,4-diazepine tetraacetic acid (AAZTA). -Mg aminopolycarboxylate / Ca aminopolycarboxylate is made from [Mg derivative / Ca derivative] and aminopolycarboxylic acids such as [EDTA / DTPA / TTHA / DTCA / EGTA / BAPTA / NOTA / DOTA / HEEDA / PEPA / HEHA / TETA / TETPA / DOTPA / DOTMP / EDDS / HEIDA / GLDA / MGDA / ASDA / CDTA / EDDS / EDDHA / DOTA / EGTA / NETA / CyDTA / GEDTA / TTHA / DO3A / AAZTA]. - Salts made from an acid having a sulfur-containing functional group on its molecule and a polyamine are salts made from a polyamine [TETA / TEPA / PEHA / branched PEI] and an acid having a sulfur-containing functional group on its molecule, such as [sulfonic acid / sulfuric acid / sulfite / sulfenic acid / sulfinic acid / hydrosulfic acid / hyposulfite]. - Salts made from an acid having at least two carboxyl-containing functional groups on its molecule and a polyamine are salts made from a polyamine [TETA / TEPA / PEHA / HEPA / HEEDA / PEPA / PEI / branched PEI] and an acid having at least two carboxyl-containing functional groups on its molecule, such as [gluconic acid / fumaric acid / itaconic acid / glutamic acid / aspartic acid / carbonic acid / phosphoric acid / citric acid / succinic acid / malic acid]. - Salts made from an acid having at least two hydroxyl-containing groups on its molecule and a polyamine are salts made from a polyamine [TETA / TEPA / PEHA / branched PEI] and an acid having at least two hydroxyl-containing functional groups on its molecule, such as ascorbic acid / tannic acid / tannic acid.

[0068] While one unit of the synthetic chelator described above can capture 80 to over 200 units of [Zn ions / other transition metal ions], one unit of a natural chelator (e.g., one unit of lysine phosphate / lysine chloride / arginine phosphate / arginine chloride) can capture one unit (or several units) of [Zn ions / other transition metal ions]. This helps to understand that the chelators of the chelator drugs of the present invention have abilities such as rapidly relieving symptoms / preventing the appearance of post-disease syndromes / weakening pathogenic microorganisms / strengthening the immune system / preventing cancer metastasis / inactivating toxins and neurotoxins / recovering the host body from many different diseases, far exceeding the capabilities of natural chelators present in the host body.

[0069] The chelator agent / chelator-strong physical effect agent / chelator-form-strong physical effect agent of the present invention has the following effects and the following mechanism of action when present in the host body / host affected tissue (the host is an animal / human). Thanks to a drug chelator, which isolates [toxins / neurotoxins] and [Zn / other transition metal]-rich products (released from pathogens and their fragments, known as pathogenic microorganisms) that are symptom-causing factors from host metalloproteins, the symptoms of disease caused by pathogenic microorganisms (including dangerous symptoms / dangerous neurological symptoms) are rapidly eliminated. The chelator then captures the [Zn / other transition metal-rich products], which are then removed from the patient's body by urine. • A drug chelator to isolate toxins / neurotoxins from host metalloproteins, and then, thanks to a chelator that captures toxins / neurotoxins that would otherwise be removed from the patient's body by urine, the toxicity of toxins / neurotoxins (including toxins / neurotoxins produced by pathogenic microorganisms in the patient's body / external toxins or external neurotoxins entering the host's body from outside) is rapidly lost. • Inactivating pathogenic microorganisms thanks to drug chelators, which sequester Zn ions / transition metal ions on metalloproteins on the surface of pathogenic microorganisms (on the surface of spike proteins in pathogenic viruses), causing the pathogenic microorganisms to lose the ability to bind to metalloproteins on / on the host cell membrane / receptors on the host cell membrane, and causing the pathogenic microorganisms to lose the ability to attack / penetrate host cells. • The pathogenic microorganisms convert Zn derivatives / other metal derivatives in the host body, which are a source of raw materials required by the microorganisms, into Zn chelates / transition metal chelates that the microorganisms cannot use for their rapid growth / rapid proliferation, thus weakening the pathogenic microorganisms. Healthy host cells can still be used because they proliferate / grow very slowly. The cytokine storm is rapidly eliminated thanks to a drug chelator that sequesters [Zn / other transition metal]-rich products (from pathogenic microorganisms) from metalloproteins on the host cell membrane / receptors on the host cell membrane. The chelator, which then captures the toxins / neurotoxins that are removed from the patient's body by urine, causes leukocytes to no longer mistake these host cells for pathogenic microorganisms (the surface of pathogenic microorganisms has a high density of Zn ions / transition metal ions that help them bind to metal ions on host cell metalloproteins). Thus, leukocytes no longer attack these host cells, and thereby the cytokine storm is no longer present. Thanks to a drug chelator that rapidly dissolves suspensions composed of Zn-rich products (from microorganisms) and their fragments, as well as Zn-blood complexes formed from blood, the symptoms of blood viscosity / tissue fluid viscosity / alveolar fluid viscosity are rapidly relieved. • Rapid loss of blood coagulation is achieved thanks to drug chelators that break down Zn crosslinks on the surface of platelets (these are made from Zn-rich products (from microorganisms and their fragments), which cause platelets to stick together, and the aforementioned Zn-blood complex suspension particles to stick to the surface of platelets, thereby dissolving the blood coagulation). Thanks to drug chelators that strongly reduce the voltage of metalloprotein electrode pairs in nerve tissue, neurological symptoms (e.g., loss of taste / loss of appetite / sore throat / cough / muscle pain / headache / fever, etc.) are rapidly relieved, helping to normalize the voltage of the electrode pairs in nerve tissue, thereby eliminating neurological / inflammatory symptoms. Thanks to drug chelators that capture Cu ions in the patient's blood (free Cu derivatives that appear in the body of a patient whose body is depleted of polyamine derivatives capable of capturing Cu ions. The Cu ions in these free Cu derivatives bind to Fe ions on metalloproteins of [red blood cells / alveolar cells / other host cells], causing these cells to lose their ability to exchange O2, which causes the patient to suffer from respiratory failure / acute respiratory failure), the symptoms of respiratory failure / acute respiratory failure are rapidly relieved, causing [red blood cells / alveolar cells / other host cells] to quickly return to normal O2 exchange, thereby helping the patient rapidly recover respiratory activity. • Metastatic cancer cells that have left cancerous tissue are inactivated thanks to drug chelators that block Zn ions / transition metal ions on metalloproteins on the surface of metastatic cancer cells that have left cancerous tissue. This causes metastatic cancer cells that have left cancerous tissue to lose their ability to bind to metalloproteins on the host cell membrane / receptors on the host cell membrane, thereby causing metastatic cancer cells that have left cancerous tissue to lose their ability to metastasize to healthy cells / healthy tissues. • Reduces / eliminates the accumulation of [Zn ions / Zn ions-other transition metal ion complexes] in nerve tissue / brain tissue, thereby reducing / eliminating numerous syndromes (e.g., post-Covid / dementia syndrome, tremor syndrome, or cataract syndrome in the elderly (these syndromes in the elderly appear due to a gradual decrease in the amount of polyamine derivatives in the body over time)), and prevents the accumulation of [Zn ions / Zn ions-other transition metal ion complexes] in the elderly from being more effectively cleansed by polyamine derivatives. This method drastically reduces the voltage of the metalloprotein electrode pairs in living organisms (including healthy cells / healthy tissues / pathogenic microorganisms / pathogenic microorganisms / cancer cells / cancerous cells), significantly reducing the polarity of metalloproteins in living organisms within the patient's body, thereby paving the way for various drugs when used in conjunction with a chelator to increase their permeability into living organisms. Thanks to this, the dosage of different drugs is greatly reduced. At the same time, despite the very small dosages of these different drugs, their efficacy is greatly increased. In particular, the dosage of antibiotics can be greatly reduced, and at the same time, antibiotics that pathogenic microorganisms are resistant to can be reused. ·A solution containing a chelator with strong [Zn ions / other transition metal ions] scavenging properties + high concentration of polyols / a solution containing a chelator with strong [Zn ions / other transition metal ions] scavenging properties + peroxide + high concentration of polyols is needed to break down the transition metal crosslinks on / between metal proteins of [cancer cells / cancer syncytium / cancer tissue] when present in cancerous tissue (these are crosslinks that cause the size of [cancer cells / cancer syncytium / cancer tissue] to continuously increase), causing cancer cells to die / cancer syncytium to disintegrate / cancer tissue to decrease in size.Therefore, to date, there are no drugs in the form of a solution containing a chelator with strong [Zn ions / other transition metal ions] scavenging properties + high concentration of polyols / a solution containing a chelator with strong [Zn ions / other transition metal ions] scavenging properties + peroxide + high concentration of polyols for treating cancerous tissue (and also for treating benign tumors). • Thanks to drug chelators, which are involved in strengthening the host's immune system, they bind to [Cu ions / Mg ions / Ca ions] structurally in [antibacterial alkaline peptides / antibody proteins / intraleukocyte bactericidal proteins], greatly increasing the ability of [antibacterial alkaline peptides / antibody proteins / intraleukocyte bactericidal proteins] to kill pathogenic microorganisms, thereby strengthening the host's immune system (a strong host immune system is also due to the amount of polyamine derivatives that have the activity to capture [Zn ions / other transition metal ions] still present in the host's body). In particular, it strengthens the weakened immune system of those with [HIV / tuberculosis / several other chronic diseases / stage 3-4 cancer] (pathogenic microorganisms / pathogenic pathogenic microorganisms syncytium / cancer cells / cancer syncytium / cancer tissue are biological factories that absorb [Zn ions / other transition metal ions / citric acid / succinic acid / malic acid / gallic acid] from host tissue. Then, they release [Zn ions / other transition metal ions / citric acid / gallic acid] as waste products into the host body. Deficiency / depletion of chelating agents with [Zn ion / transition metal ion] retention properties weakens the host immune system). Depletion / depletion of chelators with [Zn ion / other transition metal ion] capture properties weakens the host immune system. • It helps to cleanse (i.e., remove) the accumulation of [Zn ions / Zn ion-other heavy metal ion complexes / other heavy metal ions] in the host's tissues / nerve tissue / brain tissue, preventing their occurrence / eliminating post-illness syndromes (e.g., post-Covid-19 syndrome / brain fog syndrome in individuals who have had Covid-19) (elimination in the chelating agent of this invention) / and reduce [dementia syndrome / tremor syndrome / cataracts, etc.] in the elderly. Furthermore, thanks to this "cleansing mechanism," the host's body is in better health after illness / when the host's body is elderly. In addition to reducing the voltage of metalloprotein electrode pairs in disease-causing organisms and the host organism, it produces a series of other physical effects. It harms pathogenic organisms but strengthens the host organism, thereby making the host body healthier / the host immune system stronger / the host more comfortable / less painful / less pathological.

[0070] All pathogenic microorganisms use high concentrations of [Zn ions / other transition metal ions] on their surface (on spike proteins in pathogenic viruses) to bind to metalloproteins / receptors on the host cell membrane, so that the metalloproteins of pathogenic microorganisms accumulate large amounts of Zn ions / other transition metal ions (due to the fact that pathogenic metalloproteins are rich in cysteine / polar amino acids, which create segments for attracting and accumulating Zn ions / other transition metal ions). After accumulating a large amount of Zn ions / other transition metal ions, the pathogenic microorganisms and their fragments release [Zn derivatives / other transition metal derivatives / Zn-other transition metal complex derivatives / [Zn / other transition metal]-rich peptides and proteins (referred to as [Zn / other transition metal]-rich products from pathogenic microorganisms) into the host body. These [Zn / other transition metal]-rich products (which are also toxins / neurotoxins) rapidly reduce the amount of chelators with [Zn ion / other transition metal ion]-capturing properties in the first stage, and rapidly reduce the amount of chelators and chelating agents with [Zn ion / other transition metal ion]-capturing properties that still have the activity to capture [Zn ion / other transition metal ion]. In the second stage, these chelators are depleted by capturing Zn ions / other transition metal ions, and the [Zn / other transition metal]-rich products bind to metalloproteins in the host cells / tissues / nerve tissue / brain tissue that are causing symptoms. The third stage is the recovery stage, during which the host body provides new chelators (mainly polyamine derivatives, e.g., histidine / lysine / arginine / ornithine / agmatine / putrescine / cadaverine / derivatives, spermidine / spermine, etc., Mg-porphyrins). These new chelators help gradually sequester [Zn / other transition metal]-rich products from pathogenic microorganisms from host metalloproteins, gradually reducing the severity of symptoms and helping the host body recover.However, recovery by these new natural chelators is lengthy (several weeks to months in unvaccinated patients), and because [Zn / other transition metal]-rich products from pathogenic microorganisms are not completely isolated from host metalloproteins by these new chelators, post-disease syndrome occurs.

[0071] The chelating agent of the present invention contains a chelator with very strong [Zn ion / other transition metal ion] scavenging characteristics. This can be detected by one chelating unit of the chelating agent of the present invention and can dissolve 80 to 200 units of a suspension consisting of Zn-blood complexes. While natural chelators are present in the host, approximately 100 units of natural chelators should be required to dissolve 100 units of a suspension consisting of Zn-blood complexes (as mentioned in the background of the invention). This chelating ability of the chelating agent of the present invention helps to understand why the chelating agent of the present invention causes such rapid symptom resolution in severe cases of diseases caused by pathogenic microorganisms (e.g., Covid-19 (human) / influenza (human) / viral fever (human) / avian influenza (clinical trials in chickens)). Symptoms were significantly reduced approximately 3-4 hours after the first oral administration / approximately 20 minutes after the first injectable administration, and patients clearly achieved a feeling of relief. However, prior to using the chelating agent of the present invention, patients (humans) had very high levels of [severe sore throat / severe cough / severe muscle pain / loss of taste / loss of appetite / fatigue / headache, etc.] that were unbearable. For example, the agent for treating Covid-19 by each dose for adults contains 1.4 g Mg EDTA / 0.8 g triethylenetetraminediethylenetriaminepentaacetic acid. The agent is administered three times a day for 7 days, and then 1 / 2 the above dose for the next 8 days to prevent the development of post-Covid syndrome. The results showed that in patients with severe Covid-19 (including patients who had not received any Covid-19 vaccination / patients older than 75 years), symptoms were significantly reduced 4 hours after the first dose. After 48 hours, there were almost no residual symptoms, and the disease was cured in the following few days. No post-COVID syndrome developed after treatment. In cases of COVID-19 with pulmonary infection, patients should use Bactrim at a dose equivalent to one-quarter of the usual dose (because when antibiotics are used concurrently with chelating agents, the effectiveness of the antibiotic is greatly increased, making the required dose of antibiotic considerably lower than the usual dose of antibiotics).

[0072] Animal / human clinical trials of the chelator agent of the present invention containing polyamine aminocarboxylic acid / salt for the treatment of certain diseases caused by microorganisms have shown that the chelator of the chelator agent of the present invention, which consists of an acid having a sulfur-containing functional group on the molecule and polyamine / Mg aminopolycarboxylate / Ca aminopolycarboxylate (Ca aminopolycarboxylate in the injection route), is exceptionally effective in treating the symptoms of diseases caused by microorganisms and has outstanding therapeutic efficacy in the treatment of diseases caused by microorganisms. The chelator of the chelator agent of the present invention containing the above chelator has the following effects: • To quickly eliminate symptoms. • Weakens pathogenic microorganisms. • Binds to Cu ions on [antibacterial alkaline peptides / antibody proteins / pathogen-killing proteins in leukocytes], inducing these peptides / proteins to increase their ability to kill pathogenic microorganisms. • Helps flush away the accumulation of [Zn ions / transition metal ions / Zn-other transition metal ion complexes] in tissues / nerve tissue / brain tissue, thereby alleviating post-illness syndromes. • To render toxins or neurotoxins intoxicated. • To generate a series of other benefits mentioned in the background of the invention.

[0073] The clinical efficacy of the chelating agents of the present invention for the treatment of the above-mentioned diseases, in conjunction with the clinical efficacy in animals infected with toxins / neurotoxins mentioned in the background of the invention above, indicates that the chelating agents of the present invention, in particular, drugs containing polyamine aminopolycarboxylates (e.g., polyamine aminopolycarboxylates made from [TETA / TEPA / PEHA / branched PEI and EDTA / DTPA / TTHA / DTCA / EGTA / BAPTA / NOTA / DOTA / HEEDA / PEPA / HEHA / TETA / TETPA / DOTPA / DOTMP / EDDS / HEIDA / GLDA / MGDA / ASDA / CDTA / EDDS / EDDHA / DOTA / EGTA / NETA / CyDTA / GEDTA / TTHA / DO3A / AAZTA], are effective in treating dangerous diseases caused by microorganisms with high / very high mortality rates (e.g., Covid 19. It helps predict that this drug can rapidly save lives in severe / critical cases of avian influenza, Ebola, Marburg disease, smallpox, chickenpox, tetanus, rabies, AIDS, anthrax, etc. (bloodborne / brainborne infections).

[0074] Polyamine aminopolycarboxylates, made from the active ingredient polyamine aminopolycarboxylate (for example, [where polyamine is TETA / TEPA / PEHA / branched PEI and aminopolycarboxylic acid is EDTA / DTPA / TTHA / DTCA / EGTA / BAPTA / NOTA / DOTA / HEEDA / PEPA / HEHA / TETA / TETPA / DOTPA / DOTMP / EDDS / HEIDA / GLDA / MGDA / ASDA / CDTA / EDDS / EDDHA / DOTA / EGTA / NETA / CyDTA / GEDTA / TTHA / DO3A / AAZTA]), are chelators that have the effect of eliminating the toxicity of toxins / neurotoxins (including toxins / neurotoxins produced by pathogenic microorganisms in the patient's body, as well as external toxins / external neurotoxins from rodenticides / insecticides / poisonous animal toxins / poisonous plants / poisonous mushrooms / toxins produced by biotechnology / some organic toxins and other inorganic toxins, etc.). The active ingredients triethylenetetraminediethylenetriaminepentaacetic acid and several other polyamine aminopolycarboxylates mentioned above have been used in the clinical treatment of small animals (e.g., Boraras microsus fish, flies and maggots, crickets, earthworms, marine worms, sipunculid worms, chickens, rats) contaminated with many types of toxins / neurotoxins that are active ingredients in rodenticides / insecticides / poisonous plants, etc. All treatments achieved the result of helping to prevent the death of the experimental animals, even when the animals were infected with toxins / neurotoxins at doses several to tens of times higher than the minimum dose that would cause death.

[0075] Clinical trials using Boraras microsus fish have shown that the active ingredient triethylenetetraminediethylenetriaminepentaacetic acid has the ability to detoxify toxins / neurotoxins.

[0076] When fish were kept in water containing [5 ppm nereistoxin + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days (up to several weeks), but when fish were kept in water containing only 5 ppm nereistoxin, the fish died after 30 minutes. When fish were kept in water containing [1.25 ppm furcumafen (1 / 4 tablet of rodenticide (0.005% furcumafen) in 1 liter of water) + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days (up to several weeks), but when fish were kept in water containing 1.25 ppm furcumafen, the fish died after 36 hours. When fish were kept in water containing [0.3 ppm bromadiolon + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 0.3 ppm bromadiolon, the fish died within 12 hours. When fish were kept in water containing [0.2 ppm methylamine avermectin + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 0.2 ppm methylamine avermectin, the fish died within 12 hours. When fish were kept in water containing [2.5 ppm emamectin benzoate + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 2.5 ppm emamectin benzoate, the fish died within a few hours. When fish were kept in water containing [1.0 ppm phenylperazole + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 1.0 ppm phenylperazole, the fish died within a few hours. When fish were kept in water containing [0.2 ppm alpha-cypermethrin + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 0.2 ppm alpha-cypermethrin, the fish died within a few hours. When fish were kept in water containing [0.3 ppm CuCl2 + 20 ppm ZnCl2 + 20 ppm FeCl3], the fish survived for several days, but when fish were kept in water containing [0.3 ppm CuCl2 + 20 ppm ZnCl2], the fish died within a few hours. These experiments help to identify that during the hemorrhagic stage of dengue fever, the patient's fever decreases and they feel better due to an increase in the concentration of Fe derivatives in the blood (from broken red blood cells). When fish were kept in water containing 2000 ppm triethylenetetraminediethylpentaacetic acid / 3000 ppm Mg EDTA / 2000 ppm Cu EDTA / 12000 ppm Ca EDTA / [10000 ppm + 2500 ppm CuCl2], the fish survived for several days, but when fish were kept in water containing 1000 ppm 2Na EDTA / 0.5 ppm CuCl2 / [0.3 ppm CuCl2 + 20 ppm ZnCl2], the fish died within a few hours. These experiments help to identify the toxicity threshold of chelators to host cells (hosts are animals / humans). Ca EDTA / Ca EDTA is highly safe and helps treat diseases caused by infections with extremely high infection levels of heavy metal derivatives / radioactive metal derivatives.

[0077] The following clinical experiment using Boraras microsus fish confirmed the ability of the active ingredient triethylenetetraminediethylenetriaminepentaacetic acid to inhibit / kill pathogenic microorganisms. A large number of Boraras microsus fish (approximately 100g) that had died after 3 days were used. Then, this amount of dead fish was placed in 10 liters of water. Live fish were kept in this 10 liters of water for 2 days so that all the fish in this 10 liters of water would be infected with pathogenic microorganisms (from the 100g of dead fish after 3 days). Then, 1 liter of water containing the above dead fish was added to each large beaker. Each beaker contained approximately 30 live fish. Then, one beaker was used as a control experiment, and the remaining beakers were filled with substances so that each container contained 10 ppm ampicillin / 20 ppm bactrim / 20 ppm ampicillin / 40 ppm bactrim / 100 ppm triethylenetetraminediethylenetriaminepentaacetic acid / 300 Mg EDTA / 600 ppm Ca EDTA / [50 ppm Cu EDTA + 100 ppm triethylenetetraminediethylenetriaminepentaacetic acid] / [0.3 ppm ampicillin + 50 ppm triethylenetetraminediethylenetriaminepentaacetic acid] / [0.6 ppm bactrim + 50 ppm triethylenetetraminediethylenetriaminepentaacetic acid]. The result was that after 6 days, all the fish in the control experiment beaker / [10 ppm ampicillin / 20 ppm bactrim / 20 ppm ampicillin / 40 ppm bactrim] beakers died, and the water in these beakers became cloudy. Six days later, all the fish in the beakers containing [100 ppm triethylenetetraminediethylenetriaminepentaacetic acid / 300 Mg EDTA / 600 ppm Ca EDTA / 50 ppm Cu EDTA + 100 ppm triethylenetetraminediethylenetriaminepentaacetic acid] / [0.3 ppm ampicillin + 50 ppm triethylenetetraminediethylenetriaminepentaacetic acid] / [0.6 ppm bactrim + 50 ppm triethylenetetraminediethylenetriaminepentaacetic acid] were alive, and the water in these beakers was clear.

[0078] The results above also suggest that when aminopolycarboxylate polyamines are present in the host's [blood / tissue fluid / alveolar fluid] at very low concentrations (over 30 ppm for aminopolycarboxylate polyamines made from TEPA / PEHA / branched PEI and DTPA, and over 60 ppm for polyamine aminopolycarboxylates formed from TETA and DTPA), their ability to inhibit / kill pathogenic bacteria far exceeds that of Bactrim at a concentration of 10 ppm or ampicillin at a concentration of 20 ppm in the host's [blood / tissue fluid / alveolar fluid].

[0079] Specifically, drugs containing the components [polyamine aminopolycarboxylate + antibiotic active ingredient] / [salt made from polyamine aminopolycarboxylate + [an acid with a sulfur-containing functional group on the molecule and a polyamine]] are highly effective at killing bacteria. Therefore, they are exceptionally effective in treating diseases caused by pathogenic microorganisms, greatly reducing the dose of the active ingredient of antibiotics / eliminating the need for antibiotics altogether. At the same time, these drugs offer a range of other benefits as described above (e.g., rapid symptom relief / cleansing the patient's body from the accumulation of Zn ions or other transition metal ions / reducing pain and inflammation, etc.).

[0080] Clinical trials of chelator-strong physical effect agents, where the active ingredient is a chelator with strong [Zn ion / other transition metal ion] scavenging properties + high concentration polyol, and chelator-foam-strong physical effect agents, where the active ingredient is a chelator with strong [Zn ion / other transition metal ion] scavenging properties + high concentration polyol + peroxide, on affected tissues (e.g., bacterial infected tissue / fungal infected tissue / fluid-containing tissue containing many toxins / benign tumors / cancerous tumors) demonstrate that these agents of the present invention have outstanding efficacy in treating the above-mentioned affected tissues. The above-mentioned agents have outstanding efficacy in treating affected tissues thanks to the strong physical effect generated in the treated tissue / [strong physical effect generated in the treated tissue + foam structure created in the affected tissue], greatly increasing the rate of degradation of the active ingredient of the agent, thereby overcoming the protection of the dense structure / high-viscosity fluid-containing structure of the affected tissue, which is a structure that protects pathogenic entities / virulence factors within the affected tissue. For example, this involves the treatment of severely infected tissue (animal / human) with topical application of a chelator drug solution containing [70% glycerol + 0.4% EDTA Cu + 1.2g EDTA Mg + 3.6g EDTA Ca + 100% water] to open wounds of infected tissue (applied four times a day on the first day, twice a day on the following day, and continued until the open wound heals (approximately 5-7 days)). Infection is significantly reduced after 1 day, the infection is completely gone after 3 days, and the open wound heals with almost no scarring after 5-7 days. The drug produces an analgesic effect (creating only a mild burning sensation in the open wound for the first few minutes after application).

[0081] Chelater-form-strong physical effect drug type has the effects of a chelater-strong physical effect drug type. In addition, chelater-form-strong physical effect drug type also has the following effects and benefits. • It pushes highly viscous fluids (containing many pathogenic microorganisms / toxins / nutrients for pathogenic microorganisms) out of infected tissue. • Rapid dispersion of glycerol and treatment components into the affected tissue. • Temporary replacement of large amounts of water in the host tissue / host cells / pathogenic microorganisms with glycerol to inhibit the activity of pathogenic microorganisms. However, it does not harm the host tissue / host cells. It softens tissue, promotes tissue healing, and helps reduce pain caused by dehydration of open wounds during tissue healing. This causes blood (containing many white blood cells / antibodies) to recirculate in the affected tissue. • Increases the dispersion rate of the active ingredient of the drug in the treated tissue. • Creates thorough contact between the active ingredient of the drug and the virulence factors / pathogenic entities in the treated tissue, thereby rapidly inactivating the virulence factors / rapidly killing the pathogenic entities in the treated tissue. • It produces many other useful physical effects, which help the treated tissue recover quickly. • It is not necessary to remove severely affected tissue from the patient's body. • Cleanse the open wound in the affected tissue once before applying the medication. • Helps reduce pain and inflammation (because chelators and polyols strongly reduce the voltage of the electrode pair of host metalloproteins in the treated tissue). Chelate / glycerol has few side effects because, at concentrations suitable for treating affected tissue, it is largely non-toxic to healthy host cells. • The active ingredients of the drug are uniformly dispersed in the affected tissue and penetrate in large quantities into the virulence factors / pathogenic entities, resulting in fewer recurrences. • Easy to implement and low treatment cost. Glycerol cleanses, softens, and increases the elasticity of the treated tissue, and strongly recirculates blood to the treated tissue, resulting in less scarring and fewer complications after treatment. As a result, the treated tissue heals more quickly.

[0082] The clinical efficacy of the above-mentioned affected tissue treatment is outstanding. This helps predict that the treatment of most affected tissues will become easier thanks to the treatment of affected tissue with the agents of the present invention. This is due to the strong physical effects produced in tissues treated with this chelator drug-strong physical effect type / this chelator drug-form-strong physical effect type of the present invention, which have outstanding efficacy far exceeding that of current drugs (current drugs are drugs that do not produce a physical effect in treated tissue / produce a physical effect that is not sufficiently strong in treated tissue). The successful clinical results of the above-mentioned agents in the treatment of many different types of affected tissue (human) help predict that the treatment of most affected tissues will become easier in the future with the treatment of affected tissue with these agents of the present invention. These agents also bring a wide variety of other benefits. For example, • It is not necessary to remove severely affected tissue from the patient's body. • It is easy to perform for the treatment of affected tissue. • Before using the medication, it is necessary to clean the open wound in the affected tissue only once. • Fewer side effects (because the active ingredient in the drug is not toxic to healthy cells / tissues during and after treatment). • Less likely to recur (because the active ingredient is uniformly dispersed in the affected tissue). • Low treatment costs. • Fewer post-treatment complications and fewer scars after treatment. • Helps prevent secondary pathogenic microorganism infection of treated tissue.

[0083] Chelating agents with strong physical effects have a chelating effect on the treated tissue. In addition, chelating agents with strong physical effects also have the following effects and benefits. • It pushes highly viscous fluids (containing many pathogenic microorganisms / toxins / nutrients for pathogenic microorganisms) out of infected tissue. • Rapid dispersion of glycerol and treatment components into the affected tissue. • Temporary replacement of large amounts of water in the host tissue / host cells / microbial bodies by glycerol. This helps inhibit the activity of pathogenic microorganisms but does not harm the host cells / host tissue. It softens tissue, promotes tissue healing, and helps reduce pain caused by dehydration of open wounds during tissue healing. This causes blood (containing many white blood cells / antibodies) to recirculate in the treated tissue. • Increases the dispersion rate of the active ingredient of the drug in the treated tissue. • Creates thorough contact between the active ingredient of the drug and the virulence factors / pathogenic entities in the treated tissue, thereby rapidly inactivating the virulence factors / rapidly killing the pathogenic entities in the treated tissue. • It produces many other useful physical effects, helping the treated tissue to heal quickly. • It is not necessary to remove severely affected tissue from the patient's body. • Before using the medication, clean the open wound in the affected tissue only once. • Helps reduce pain and inflammation (because chelating agents and polyols strongly reduce the voltage of the electrode pair of host metalloproteins in the treated tissue). Chelating agents / glycerols have few side effects because, at concentrations of chelating agents / glycerols in the treated tissue, they are substantially non-toxic to healthy host cells. • The active ingredients of the drug are uniformly dispersed in the affected tissue and penetrate in large quantities into the virulence factors / pathogenic entities, resulting in fewer recurrences. • Easy to implement and low treatment cost. Glycerol cleanses, softens, and increases the elasticity of treated tissue, and strongly recirculates blood to the treated tissue, resulting in less scarring and fewer complications after treatment. As a result, treated tissue heals more quickly.

[0084] The discovery of chelators and their physical effects in biology / the discovery of the aforementioned new chemical bonds, along with the discovery of other strong physical effects, brings a series of other significant benefits to the treatment of affected tissue thanks to the creation of foam structures in the treated tissue. As mentioned above, a series of powerful and beneficial physical effects are also produced in the treated tissue, and the treated tissue also gives it a foam structure, causing virulence factors / pathogenic entities to reside within thin walls created between microbubbles. In addition, many other beneficial physical effects are produced (e.g., continuous changes in bubble pressure that help increase the permeation of the active ingredient of the drug to the bodies / virulence factors of pathogenic entities located within the thin walls). These drugs contain components including: -[[Zn ion / other transition metal ion] scavenging characteristics chelator + agent that promotes the permeation rate of the treatment component in the treated tissue (e.g., high concentration of glycerol) + low water content] (chelator - referred to as a strong physical effect agent). - A chelator with [[Zn ions / other transition metal ions]-capturing properties + an agent that accelerates the permeation rate of the treatment component in the treated tissue (e.g., high concentration glycerol) + an agent that creates a foam structure in the treated tissue (e.g., peroxide + low water content) (referred to as a chelator-foam-strong physical effect agent). These two agents are used to treat affected tissue (e.g., bacterial infected tissue / necrotic tissue / fungal infected tissue / affected tissue containing fluids with many toxins / benign tumors / cancerous tumors). These two agent types have the following effects as chelator agent types. At the same time, they have additional effects (as mentioned in the background of the invention; these are mentioned again below to understand the valuable benefits of the agent type containing [[Zn ions / other transition metal ions]-capturing properties + an agent that accelerates the permeation rate of the treatment component in the treated tissue (e.g., high concentration glycerol) + an agent that creates a foam structure in the treated tissue (e.g., peroxide + low water content)] in treating affected tissue having a dense structure / structure containing a highly viscous fluid). • It kills microorganisms / cancer cells extremely rapidly. This is because it oxidizes Zn-Fe crosslinks / Zn-Cu-Fe crosslinks / other Zn-heavy metal crosslinks into metal oxides, causing these crosslinks to break down and leading to the rapid death of microorganisms / cancer cells (however, healthy cells remain safe because the amount of H2O2 catalyst in healthy cells is considerably lower than the amount of H2O2 catalyst in pathogenic microorganisms / cancer cells). - Rapidly oxidizes toxins in the affected tissue and rapidly eliminates the toxicity of these toxins. - Creates a foam structure in the affected tissue so that virulence factors / pathogenic entities reside within the walls formed between tiny bubbles, increasing the dispersion rate of the active ingredient of the drug in the affected tissue to a very high level. The contact between virulence factors / pathogenic entities and the active ingredient of the drug in the treated tissue becomes very thorough, helping to kill pathogenic microorganisms / cancer cells very rapidly, helping to rapidly oxidize toxins in the affected tissue, causing these toxins to rapidly lose their toxicity, and helping to create a series of beneficial mechanical effects for the treatment (e.g., increasing or decreasing bubble volume; bubbles push each other farther apart, increasing drug permeability within the bubble walls / increasing contact between the drug and pathogens and toxins in tissue disease, etc.), helping to significantly increase the effectiveness of the treatment of the affected tissue in a much shorter treatment time and helping to reduce recurrence. • Causes virulence factors / pathogenic entities to reside within thin walls formed by microbubbles (chelator-form-strong physical effect drug type), thereby increasing the dispersion rate of the drug's active ingredient in the affected tissue to a very high level, and causing the drug's active ingredient to come into complete contact with all virulence factors / pathogenic entities in the treated tissue. • The continuous changes in the pressure of the bubbles (which create thin walls) cause the active ingredient of the drug to strongly penetrate the virulence factors / pathogenic entities within the thin walls. As a result, the amount of the active ingredient of the drug that enters the virulence factors / pathogenic entities within the thin walls increases significantly, rapidly inactivating these virulence factors within the thin walls and rapidly killing the pathogenic entities. [Examples]

[0085] Implementation example - A chelating agent for treating Covid-19 disease. Used to treat patients with severe symptoms and those who have not received any Covid-19 vaccination. Patients are given the oral medication (each dose (adult dose) contains [1.4g EDTA Mg (6% Mg type)] + 2.6g water + glycerol to 5ml) (approximately a teaspoon). The drug is administered three times a day for seven days. From day 8 to day 15, half of the above dose is administered daily (additional doses are given from day 8 to prevent the onset of post-Covid syndrome). Four hours after the initial dose, symptoms are significantly reduced and the patient feels considerably better. After 48 hours, symptoms remain almost nonexistent. Then, a few days later, the disease is cured. After treatment, the patient did not develop post-Covid-19 syndrome.

[0086] - A chelating agent for treating Covid-19 disease. It was used to treat patients over 75 years of age with severe symptoms and lung infection, as well as patients who had received their previous Covid vaccine injection more than 16 months prior. Patients received the aforementioned chelating agent, administered in the same manner as described above, in combination with Bactrim at a dose of 1 / 4 of the usual dose, and Bactrim was administered for 7 days. The result was that the Covid-19 disease and lung infection were cured after 7 days.

[0087] - A chelating agent for treating influenza in a 63-year-old patient with severe symptoms. The patient was given a chelating agent containing [1.4g EDTA Mg (adult dose) 6% Mg] + 2.6g water + sufficient 5ml glycerol] (approximately 5 teaspoons) at each dose (adult dose). The agent was administered three times a day for seven days. Three hours after the first dose, most of the symptoms were significantly reduced, the patient felt considerably better, most of the symptoms disappeared after 36 hours, and the illness was over after 5 days.

[0088] - A chelating agent for treating viral fever in an 8-year-old patient with severe symptoms. The patient was given a chelating agent containing [0.7g EDTA Mg (6% Mg type)] + 1.3g water + sufficient 2.5ml glycerol (approximately 1 / 2 teaspoon) for each dose (dose for a child weighing approximately 30kg), which was half the dose compared to the adult dose. The agent was administered in three doses per day for 7 days. The results showed that the patient's fever decreased 3 hours after the first dose, and the patient returned to active exercise and appetite as before the illness. The illness was cured after 5 days.

[0089] - A chelating agent (influenza virus strain unknown) for treating avian influenza in chickens infected with avian influenza. The chicken flock had many individuals that were inactive, and many chickens began to die. 10% of the chicken flock was set aside as a control and given normal water. 90% of the chicken flock was given water containing 3% Mg EDTA. After 12 hours, the chickens that drank water containing 3% Mg EDTA ceased to be inactive and returned to a normal appetite, while the control chickens remained inactive and lost their appetite.

[0090] - A chelating agent for treating long-term COVID-19 syndrome after recovery from Covid-19. A 57-year-old male who had previously had Covid-19 and received three doses of the Covid-19 vaccine presented with a case of long-term COVID-19 syndrome. He was able to walk up four flights of stairs and experienced significantly faster breathing than before he had Covid-19. After four weeks of treatment with a chelating agent containing [0.3g triethylenetetramine neutral glutamate + 0.6g EDTA Mg] in each adult dose, administered twice daily, the man was able to walk up four flights of stairs without rapid breathing. His breathing returned to normal, as it was before Covid-19.

[0091] - A chelating agent for treating toothache symptoms caused by tooth decay. This involves using a cotton gauze pad containing a chelating agent powder [20% Ca EDTA powder + 80% zeolite powder], which is then inserted into the tooth decay. The result is that toothache symptoms gradually decrease after about 10 minutes, and the pain disappears after about 15 minutes.

[0092] - A chelating agent to treat the symptom of taste loss in COVID-19. This involves holding a drug solution containing 2% Ca EDTA in the mouth for several minutes, then spitting it out. The result is the immediate return of sweetness, a clear recovery of the loss of taste for sweeteners produced by sugarcane sugar / aspartame / sucralose.

[0093] - A chelating agent for treating sore throat / cough symptoms in diseases caused by microorganisms. Each 2g lozenge contains [0.3g Ca EDTA + 0.6g glycerol + 1g gelatin + sufficient 2g water]. Results show that sore throat / cough symptoms are reduced after being held in the mouth for about 10 minutes, and after being held in the mouth many times (when used in high doses, Ca EDTA is highly safe, so many of these chelating agent lozenges can be held in the mouth for 24 hours (adults can use less than 120g of Ca EDTA at 20g doses for 24 hours with 4 hours between doses, and still have no side effects)).

[0094] - A chelating agent for treating symptoms of dry eye / eye pain / red eyes by being dropped into the eye. A chelating agent solution containing [0.1% triethylenetetraminediethylenetriaminepentaacetic acid (neutral) + sufficient 100% water] can be dropped 2 to 6 times a day. The result is that after dropping the above solution for a few minutes, symptoms of dry eye / eye pain will no longer be present, and symptoms of red eyes will decrease after a few hours.

[0095] - A chelating agent for treating headaches of unknown origin. Each dose (adult dose) contains 0.5 g of triethylenetetraminediethylenetriaminepentaacetic acid, administered (may be in pill form). The result is a significant reduction in headache symptoms approximately 2 hours later.

[0096] - Chelating agents for treating post-COVID syndrome, such as shortness of breath during strenuous exercise (e.g., in the case of a 57-year-old male patient with severe symptoms of COVID, without the use of chelating agents to treat COVID-19, such as shortness of breath when climbing stairs (which was not present before COVID-19)). This patient's post-COVID syndrome was treated with a chelating agent containing [0.5g Mg EDTA + 1g glycerol + 2g water] in each dose, administered twice daily for one month. The results showed that after one week, shortness of breath during strenuous exercise was significantly reduced, and after one month of treatment, shortness of breath during strenuous exercise was no longer present, and the treated person felt as comfortable as before the COVID-19 illness.

[0097] - A chelating agent for treating diseases caused by toxins. The toxin is a rodenticide with furocumafen as its active ingredient. Mice in cages are fed pills containing furocumafen. After 12 hours, a container of an aqueous solution containing a chelating agent with 0.3% triethylenetetraminediethylenetriaminepentaacetic acid as its active ingredient is placed in the mouse cage. The result was that the mice were still alive after many days. However, in a control cage where mice were fed the above rodenticide and only the water container contained ordinary water, the result was that all mice died after about 2 days.

[0098] - A chelating agent for treating diseases caused by toxins / neurotoxins. This is achieved by raising Boraras micros in water containing a chelating agent whose active ingredient is triethylenetetraminediethylenetriaminepentaacetic acid. Clinical trials in animals (e.g., Boraras micros) were conducted and achieved with the following results: When fish were kept in water containing [5 ppm nereistoxin + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days (up to several weeks), but when fish were kept in water containing only 5 ppm nereistoxin, the fish died after 30 minutes. When fish were kept in water containing [1.25 ppm furcumafen (1 / 4 tablet of rodenticide (containing 0.005% furcumafen) in 1 liter of water) + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days (up to several weeks), but when fish were kept in water containing 1.25 ppm furcumafen, the fish died after 36 hours. When fish were kept in water containing [0.3 ppm bromadiolon + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 0.3 ppm bromadiolon, the fish died within 12 hours. When fish were kept in water containing [0.2 ppm methylamine avermectin + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 0.2 ppm methylamine avermectin, the fish died within 12 hours. When fish were kept in water containing [2.5 ppm emamectin benzoate + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 2.5 ppm emamectin benzoate, the fish died within a few hours. When fish were kept in water containing [1.0 ppm phenylperazole + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 1.0 ppm phenylperazole, the fish died within a few hours. When fish were kept in water containing [0.2 ppm alpha-cypermethrin + 50-300 ppm triethylenetetraminediethylenetriaminepentaacetic acid], the fish survived for several days, but when fish were kept in water containing only 0.2 ppm alpha-cypermethrin, the fish died within a few hours.

[0099] - A chelator-physical agent for treating severely infected human tissue that has previously been treated with multiple antibiotics (topical and oral) for more than one week without improvement. These infected tissues are treated by applying the above drug solution to open wounds on the infected tissue 4-6 times / day for 7 days, and by application with a chelator-physical agent containing [0.4% Cu EDTA + 1.2% Mg EDTA + 2.4% Ca EDTA + 70% + 100% water]. The results show that after 24 hours, the infection / inflammation of the treated tissue is significantly reduced, after 3 days the treated tissue is completely free of infection / inflammation, and after 7 days the open wounds of the treated tissue heal and the treated tissue heals.

[0100] - A drug for treating dark, benign tumors under the skin (in humans) with a diameter of approximately 8 mm. Application to an open wound on the tumor (the open wound is created by incising the surface of the tumor with a needle), and application approximately 6 times / day for 10 days, by application with a chelator containing [0.4% Cu EDTA + 1.2% Mg EDTA + 2.4% Ca EDTA + 0.5% triethylenetetramine diethylenetetramine pentaacetic acid + 70% glycerol + sufficient 100% water] - a strong physical effect drug. Results: After 3 days, the tumor size is clearly reduced, and a hard core appears in the center of the treated tumor. After 7 days, this core becomes even harder and shrinks. After 19 days, this hard core falls off from the treated tumor. After 10 days, the open wound heals, and the surface of the treated tumor is as flat as the surface of the skin, leaving almost no scar.

[0101] - A chelator-physical effect agent for treating melanoma tumors (human) with a diameter of approximately 12 mm. This is done by injecting a solution of the chelator-physical effect agent containing [0.4% Cu EDTA + 1.2% Mg EDTA + 2.4% Ca EDTA + 0.5% triethylenetetramine diethylenetetramine pentaacetic acid + 70% glycerol + sufficient 100% water] into the tumor. The results are similar to those for treating dark-colored benign tumors mentioned in the above section.

[0102] Chelating foam - a physiotherapy agent for treating fungal infections (human) that are warts (tissue that proliferates due to the HPV virus) measuring 4mm to 10mm in size. Treatment involves applying the chelating foam - a physiotherapy agent containing [0.4% Cu EDTA + 1.2% Mg EDTA + 2.5% triethylenetetramine diethylenetetramine pentaacetic acid + 70% glycerol + 10% H2O2 + sufficient 100% water] to the surface of these warts. Apply for 5 days, 4 to 6 times a day. The result is that after 3 days, a dry, hard core appears in the center of the treated tissue. After 6 days, this dry, hard core falls off from the treated tissue, and after a few days, the surface of the treated tissue becomes as flat as the surrounding skin surface, leaving almost no scar.

[0103] - A chelator solution for treating the environment with a composition containing [1% Ca EDTA + 1% propylene glycol + 100% water]. The chelator solution may be sprayed into the room where a person with Covid-19 is present, approximately 5 minutes before a caregiver enters the room and comes into contact with the Covid-19 patient (both wearing masks, and the drug solution was also sprayed onto the caregiver's mask. After 15 days, the caregiver did not contract Covid-19).

[0104] - A chelator solution for treating the environment with a composition containing [10% Ca EDTA + sufficient 100% water]. The solution is sprayed onto the water surface in a still / slow-flowing waterway where schools of fish are floating and already dying. The fish are poisoned by toxins (water-soluble toxins) that accumulate on land during the dry season. The result was that in the treated water surface area described above, the fish dived after about 10 minutes, while in the untreated water surface area, the fish remained floating, and after several hours, some of these floating fish died.

[0105] A chelating beauty cream for treating acne and improving skin properties, comprising a composition containing [0.5% triethylenetetraminediethylenetetraminepentaacetic acid + 10% glycerol + 1% triethylenetetraminericinoleic acid + 2% triethylenetetraminestearic acid + sufficient 100% water]. The cream is used to apply to skin areas with acne / melasma (caused by heavy metal accumulation, for example, by the accumulation of Hg from cosmetics containing Hg, or by the accumulation of heavy metals due to low concentrations of polyamine derivatives in the skin over time) / dry skin areas / inelastic skin areas. The results will be that after applying the above beauty cream to the above skin areas for one week, at least once a day, acne will be significantly reduced / disappeared, and the mechanical properties / moisture of the skin will be significantly improved. After 6 months, melasma will be significantly reduced / disappeared.

[0106] - A chelator solution for treating the environment with a composition containing [3% Ca EDTA + sufficient 100% water]. The solution is intended for treating water contaminated with heavy metals in fish canals / ponds. Here, at the beginning of the rainy season, water rich in heavy metal derivatives flowing from land into these canals / ponds causes fish to float and die. The result is that 20 minutes after uniformly spreading the above chelator solution on the surface of the water where the fish are floating, the fish will dive and will not die.

[0107] - The food preservation chelator additive has a composition containing [2% triethylenetetraminediethylenetetramine pentaacetic acid + sufficient 100% water]. The solution is sprayed onto the surface of food / mixed into processed foods (e.g., pâté) to prevent obvious toxins / neurotoxins from being produced in foods that are to be stored for a long time, thus avoiding contamination by toxin / neurotoxin-producing microorganisms. Due to triethylenetetraminediethylenetetramine pentaacetic acid, it prevents the growth of organic matter-degrading microorganisms while inactivating toxins / neurotoxins at low concentrations (greater than 30 ppm). Therefore, when the above additive is added to processed foods in a pulverized form at a concentration greater than 30 ppm, these additives will prevent the risk of poisoning to the user.

[0108] A chelating solution for hand washing, surface disinfection, and spraying in human living environments. The chelating solution has a composition containing [2% Ca EDTA + 1% propylene glycol + 70% alcohol + sufficient 100% water]. After the alcohol and water evaporate from the sterilized surface, [Ca EDTA + propylene glycol] remains on the sterilized surface, which is highly permeable to pathogenic microorganisms and immediately kills them immediately after the alcohol and water evaporate from the sterilized surface containing the chelating solution.

[0109] Chelating additives are used to preserve blood (blood used for transfusion). These additives help prevent blood clotting, help transfused blood have the ability to resist bacteria, treat diseases caused by microorganisms, or strengthen the immune system. Chelating additives have a composition containing triethylenetetraminediethylenetetraminepentaacetic acid, which is added to blood for transfusion. The concentration of triethylenetetraminediethylenetetraminepentaacetic acid in blood for transfusion is 100 ppm to 1000 ppm.

[0110] A chelator solution for preserving tissue awaiting transplantation has a composition containing [2000 ppm triethylenetetraminediethylenetetramine pentaacetic acid + 30% glycerol + sufficient 100% water]. This chelator solution is used for preserving living tissue in an environment of 1 to 4 degrees Celsius temperature while awaiting tissue transplantation. Tissue prepared for transplantation is placed in cold water at 1 degree Celsius until the glycerol concentration in the tissue decreases to less than 10%, after which it can be transplanted. In a living tissue preservation solution made from triethylenetetraminediethylenetetramine pentaacetic acid and glycerol, the biological structure of the tissue is thus less damaged, the physical structure of the tissue is less damaged, and therefore, when these tissues are transplanted, they are less likely to be rejected and less likely to become infected. After transplantation, it is necessary for the patient to receive the chelator drug for a sufficiently long time to help avoid graft rejection.

[0111] A chelator solution for use in open surgery has a composition containing [500 ppm triethylenetetraminetriethylenetetraminepentaacetic acid + 20% glycerol + 5% propylene glycol + sufficient water]. The solution is applied to the exposed tissue where the open surgery is performed. This chelator solution helps prevent infection of open wounds and helps wounds heal quickly after suturing following surgery (experiments applying the above solution to open wounds in infected skin showed that the infection disappeared quickly, pain was reduced in particular, the treated tissue recovered quickly, and the treated tissue was kept moist thanks to the glycerol. The chelator cleanses the treated tissue from the accumulation of Zn ions / other transition metal ions, which helps the treated tissue recover quickly).

Claims

1. A drug containing a chelator / chelator combination having the effect of capturing Zn ions / other transition metal ions, wherein the chelator is a salt formed from aminopolycarboxylic acid and polyamine / a salt formed from aminopolycarboxylic acid and aminopolyol / a salt formed from an acid having at least two carboxyl functional groups on the molecule and a polyamine / a salt formed from an acid having at least two hydroxyl groups on the molecule and a polyamine / a salt formed from an acid having at least one sulfur-containing functional group on the molecule and a polyamine / a salt formed from ascorbic acid and polyamine / Mg aminopolycarboxylate salt / Ca aminopolycarboxylate salt / Cu aminopolycarboxylate A drug is a drug which involves a salt / Fe aminopolycarboxylate salt / Ag aminopolycarboxylate salt / other aminopolycarboxylic acids to form an aminopolycarboxylic acid derivative having at least three carboxyl groups on the molecule; another aminopolycarboxylic acid derivative in which an aminopolycarboxylic acid is involved in forming an aminopolycarboxylic acid derivative having at least three carboxyl-containing groups on the molecule; and another polyamine derivative in which a polyamine is involved in forming a polyamine derivative having at least four nitrogen-containing functional groups on the molecule, and the drug is used for the following purposes: - To prevent or treat symptoms such as throat irritation, sore throat, throat inflammation, cough, fever, loss of taste, fatigue, muscle pain, joint pain, loss of appetite, rash, cytokine storm, headache, chills, cognitive decline, difficulty breathing, respiratory distress, acute respiratory failure, and other symptoms caused by excessive accumulation of Zn ions or other heavy metal ions in tissues / nerve tissue / brain tissue, or - To prevent or treat diseases caused by pathogenic microorganisms that result from excessive accumulation of Zn ions or other heavy metal ions in tissues / nerve tissue / brain tissue, causing symptoms such as throat irritation / sore throat / inflammation / cough / fever / loss of taste / fatigue / muscle pain / joint pain / loss of appetite / rash / cytokine storm / headache / chills / cognitive impairment / difficulty breathing / respiratory distress / acute respiratory failure / other symptoms, or, - To prevent or treat diseases caused by toxins or neurotoxins, wherein the toxin or neurotoxin is a toxin or neurotoxin produced by pathogenic microorganisms in the host body, or wherein the toxin or neurotoxin is an external toxin or external neurotoxin, and the external toxin or external neurotoxin may be an insecticide / rodenticide or other animal control agent / poisonous animal poison / poisonous mushroom / poisonous plant / organisms whose bodies contain toxins / toxins produced by biotechnology / organic toxin or inorganic toxin, or - To prevent or treat post-disease syndrome caused by the accumulation of Zn ions / Zn-other heavy metal ion complexes in host tissues / nerve tissue / brain tissue while the host has a disease caused by pathogenic microorganisms, or caused by the accumulation of Zn ions / Zn-other heavy metal ion complexes in host tissues / nerve tissue / brain tissue due to low concentrations of polyamine derivatives in the host's blood over a long period of time, or - To prevent or treat post-disease syndromes that appear after a host has suffered a disease caused by pathogenic microorganisms, or - To prevent or treat the syndrome in the elderly, or to strengthen the immune system of the elderly, - To strengthen the weakened immune system in chronic diseases, or, - To form a drug type with a higher therapeutic effect by combining it with other active therapeutic ingredients, or to form a drug type with a lower content of another active therapeutic ingredient, or - To form a drug type having a higher therapeutic efficacy than the therapeutic efficacy of the antibiotic active ingredient alone, or to form a drug type having a low content of the antibiotic active ingredient, or - To form a drug type for treating affected tissues that may be bacterially infected tissue / necrotic tissue / fungally infected tissue / tissue containing fluids with many toxins / dark-colored benign tumors / cancerous tissue by combining with polyols with a concentration of more than 20%.

2. An agent having the components and effects used for the purposes of claim 1, wherein the polyamine derivative is made from a polyamine having at least four nitrogen-containing functional groups, where the polyamine molecule having at least four nitrogen-containing functional groups on the molecule is triethylenetetramine / tetraethylenepentamine / pentaethylenehexamine / higher ethylene polyamine / N-(2-hydroxyethyl)ethylenediamine / polyethylenepolyamine / polyethyleneimine / branched polyethyleneimine / 1,1,1-tris(aminomethyl)ethane / ethoxylated poly(ethyleneimine) / polylysine / polyarginine / poly(amideamine).

3. The aminopolycarboxylic acid has at least three carboxyl-containing functional groups on its molecule that are involved in forming an aminopolycarboxylic acid derivative, where the aminopolycarboxylic acid having at least three carboxyl groups on its molecule is ethylenediaminetetraacetic acid / diethylenetriaminepentaacetic acid / triethylenetetramine-N,N,N',N'',N''',N'''-hexaacetic acid / 1,2-cyclohexylenediaminetetraacetic acid / dibenzothiophene-1,3,6,8-tetracarboxylic acid / N-hydroxyethyl-ethylenediamine-triacetic acid / trimethylenediamine Tetraacetic acid / ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid / 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid / 1,4,7-triazacyclononane-1,4,7-triacetic acid / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid / N,N'-bis(2-hydroxyethyl)ethylenediamine-N,N'-diacetic acid / 1,4,7,10,13-pentazocyclopentadecane pentaacetic acid / 1,4,7,10,13,16-hexazocyclooctadecane hexaacetic acid / 1,4,8, 11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid / triethylenetetramine pentaacetic acid / 4,5-diphenyl-1,3-oxazole-2-yl)thio](phenyl)acetic acid / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid / ethylenediamine-N,N'-disuccinic acid / 2-hydroxyethyliminodiacetic acid / glutamic acid diacetic acid / methylglycine diacetic acid / l-aspartic acid N,N-diacetic acid / ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) / ethylene glycol bis(2 An agent having the components and effects used for the purposes of claim 1, wherein the components are: -aminoethyl ether)-N,N,N',N'-tetraacetic acid / [2-{4,7-biscarboxymethyl(1,4,7)triazacyclonona-1-yl-ethyl}carbonylmethylamino]acetic acid / 1,2-cyclohexylenedinitrilotetraacetic acid / O,O'-bis(2-aminoethyl)ethylene glycol-N,N,N',N'-tetraacetic acid / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid / 6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid.

4. The salt is formed from an aminopolycarboxylic acid and a polyamine, where the polyamine is a polyamine such as lysine / arginine / spermidine / spermine / triethylenetetramine / tetraethylenepentamine / pentaethylenehexamine / higher ethylenepolyamine / N-(2-hydroxyethyl)ethylenediamine / polyethylenepolyamine / polyethyleneimine / branched polyethyleneimine / 1,1,1-tris(aminomethyl)ethane / ethoxylated poly(ethyleneimine) / polylysine / polyarginine / poly(amideamine), and the aminopolycarboxylic acid is ethoxy Diadiaminetetraacetic acid / Diethylenetriaminepentaacetic acid / Triethylenetetramine-N,N,N',N'',N''',N'''-hexaacetic acid / 1,2-Cyclohexylenediaminetetraacetic acid / Dibenzothiophene-1,3,6,8-tetracarboxylic acid / N-Hydroxyethyl-ethylenediamine-triacetic acid / Trimethylenediaminetetraacetic acid / Ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid / 1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid / 1,4,7-Triazacyclononane-1,4,7-triacetic acid / 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid / N,N'-bis(2-hydroxyethyl)ethylenediamine-N,N'-diacetic acid / 1,4,7,10,13-pentazocyclopentadecane pentaacetic acid / 1,4,7,10,13,16-hexazocyclooctadecane hexaacetic acid / 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid / triethylenetetramine pentaacetic acid / 4,5-diphenyl-1,3-oxazole-2-yl)thio](phenyl)acetic acid / 1,4,7,10-Tetraazacyclododecane-1, 4,7,10-Tetramethylenephosphonic acid / Ethylenediamine-N,N'-Disuccinic acid / 2-Hydroxyethyliminodiacetic acid / Glutamate diacetic acid / Methylglycine diacetic acid / l-Aspartate N,N-diacetic acid / Ethylenediamine-N,N'-Bis(2-Hydroxyphenylacetic acid) / Ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-Tetraacetic acid / [2-{4,7-Biscarboxymethyl(1,4,7)triazacyclonona-1-yl-ethyl}carbonylmethylamino]acetic acid / 1,2-Cyclohexylenedinitrilotetraacetic acid / O,An agent having components and effects used for the purposes described in claim 1, formed from an aminopolycarboxylic acid which is O'-bis(2-aminoethyl)ethylene glycol-N,N,N',N'-tetraacetic acid / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid / 6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid.

5. Derivatives of aminopolycarboxylic acid include Mg aminopolycarboxylate / Ca aminopolycarboxylate / Cu aminopolycarboxylate / Fe aminopolycarboxylate / Ag aminopolycarboxylate, which are formed from an aminopolycarboxylic acid and a Mg derivative / Ca derivative / Cu derivative / Fe derivative / Ag derivative, and this aminopolycarboxylic acid is ethylenediaminetetraacetic acid / diethylenetriaminepentaacetic acid / triethylenetetramine-N,N,N',N'',N''',N'''-hexaacetic acid / 1,2-cyclohexylenediaminetetraacetic acid Acid / dibenzothiophene-1,3,6,8-tetracarboxylic acid / N-hydroxyethyl-ethylenediamine-triacetic acid / trimethylenediaminetetraacetic acid / ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid / 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid / 1,4,7-triazacyclononane-1,4,7-triacetic acid / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid / N,N'-bis(2-hydroxyethyl)ethylenediamine-N,N'-diacetic acid / 1,4 ,7,10,13-pentazocyclopentadecane pentaacetic acid / 1,4,7,10,13,16-hexazocyclooctadecane hexaacetic acid / 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid / triethylenetetramine pentaacetic acid / 4,5-diphenyl-1,3-oxazole-2-yl)thio](phenyl)acetic acid / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid / ethylenediamine-N,N'-disuccinic acid / 2-hydroxyethyliminodiacetic acid / glutamic acid diacetic acid / methylglutamic acid Lysine diacetic acid / l-aspartate N,N-diacetic acid / ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) / ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid / [2-{4,7-biscarboxymethyl(1,4,7)triazacidone-1-yl-ethyl}carbonylmethylamino]acetic acid / 1,2-cyclohexylenedinitrilotetraacetic acid / O,O'-bis(2-aminoethyl)ethylene glycol-N,N,N',N'-tetraacetic acid] / 1,4,7,10-tetraazacyclododecane-1,4,7,A component and agent having the effect used for the purpose described in claim 1, wherein the component is 10-tetraacetic acid / 6-amino-6-methylperhydro-1,4-diazepinetetraacetic acid.

6. An agent having components and effects for use for the purposes of claim 1, wherein the salt is formed from an acid having at least two carboxyl-containing functional groups on its molecule and a polyamine, the polyamine being lysine / arginine / spermidine / spermine / triethylenetetramine / tetraethylenepentamine / pentaethylenehexamine / higher ethylene polyamine / N-(2-hydroxyethyl)ethylenediamine / polyethylenepolyamine / polyethyleneimine / branched polyethyleneimine / 1,1,1-tris(aminomethyl)ethane / ethoxylated poly(ethyleneimine) / polylysine / polyarginine / poly(amideamine), and the acid having at least two carboxyl-containing functional groups on its molecule is fumaric acid / itaconic acid / glutamic acid / aspartic acid / carbonic acid / phosphoric acid / citric acid / succinic acid / malic acid.

7. An agent having components and effects for use for the purposes of claim 1, wherein the salt is formed from a polyamine and an acid having at least one sulfur-containing functional group on its molecule, the polyamine being lysine / arginine / spermidine / spermine / triethylenetetramine / tetraethylenepentamine / pentaethylenehexamine / higher ethylene polyamine / N-(2-hydroxyethyl)ethylenediamine / polyethylenepolyamine / polyethyleneimine / branched polyethyleneimine / 1,1,1-tris(aminomethyl)ethane / ethoxylated poly(ethyleneimine) / polylysine / polyarginine / poly(amideamine), and the acid having at least one sulfur-containing functional group on its molecule is sulfonic acid / sulfuric acid / sulfite / sulfenic acid / sulfinic acid / hydrosulfide / hyposulfite.

8. An agent having components and effects for use for the purposes of claim 1, wherein the salt is formed from an acid having at least two hydroxyl-containing functional groups on its molecule and a polyamine, the polyamine being lysine / arginine / spermidine / spermine / triethylenetetramine / tetraethylenepentamine / pentaethylenehexamine / higher ethylene polyamine / N-(2-hydroxyethyl)ethylenediamine / polyethylenepolyamine / polyethyleneimine / branched polyethyleneimine / 1,1,1-tris(aminomethyl)ethane / ethoxylated poly(ethyleneimine) / polylysine / polyarginine / poly(amideamine), and the acid having at least two hydroxyl-containing functional groups on its molecule is ascorbic acid / gluconic acid / gluconic acid / tannic acid.

9. The salt is formed from an aminopolycarboxylic acid and an aminopolyol, where the aminopolyol is monoethanolamine / diethanolamine / triethanolamine / 2-amino-2-methyl-1-propanol / methyldiethanolamine, and the aminopolycarboxylic acid is ethylenediaminetetraacetic acid / diethylenetriaminepentaacetic acid / triethylenetetramine-N,N,N',N'',N''',N'''-hexaacetic acid / 1,2-cyclohexylenediaminetetraacetic acid / dibenzothiophene-1,3,6,8-tetracarboxylic acid / N-hydro Xyethyl-ethylenediamine-triacetic acid / trimethylenediaminetetraacetic acid / ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid / 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid / 1,4,7-triazacyclononane-1,4,7-triacetic acid / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid / N,N'-bis(2-hydroxyethyl)ethylenediamine-N,N'-diacetic acid / 1,4,7,10,13-pentazocyclopentadecane pentaacetic acid / 1,4, 7,10,13,16-Hexazocyclooctadecane hexaacetic acid / 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-Tetraacetic acid / Triethylenetetramine pentaacetic acid / 4,5-Diphenyl-1,3-Oxazole-2-yl)thio](phenyl)acetic acid / 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetramethylenephosphonic acid / Ethylenediamine-N,N'-Disuccinic acid / 2-Hydroxyethyliminodiacetic acid / Glutamate diacetic acid / Methylglycine diacetic acid / l-Aspartate N,N-diacetic acid / Ethylene Diamine-N,N'-bis(2-hydroxyphenylacetic acid) / ethylene glycol bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid / [2-{4,7-biscarboxymethyl(1,4,7)triazacid-1-yl-ethyl}carbonylmethylamino]acetic acid / 1,2-cyclohexylenedinitrilotetraacetic acid / O,O'-bis(2-aminoethyl)ethylene glycol-N,N,N',N'-tetraacetic acid / 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid / 6-amino-6-methylperhydro-1,A drug having the components and effects used for the purposes described in claim 1, which is a salt formed from an aminopolycarboxylic acid that is 4-diazepinetetraacetic acid.

10. A drug having components and effects for use for the purposes described in any one of claims 1 to 9, wherein the drug component comprises Mg derivative / Ca derivative / Cu derivative / Fe derivative / Zn derivative / polyol / surfactant / boron derivative / peroxide.

11. A drug having components and effects for use for the purposes described in any one of claims 1 to 10, wherein the drug contains at least one additional therapeutic active ingredient different from the therapeutic active ingredient described in claim 1.

12. A drug having components and effects used for the purposes described in claim 11, wherein the other active ingredients are an antibiotic active ingredient / an antifungal active ingredient / an anti-inflammatory active ingredient / analgesic active ingredient / an active ingredient that reduces soft tissue pain / an active ingredient that reduces bone tissue pain / an active ingredient that reduces joint tissue pain / an active ingredient that reduces headaches / an active ingredient that kills cancer cells.

13. A drug having components and effects for use for any one of claims 1 to 11, wherein the drug is in solution form and contains a polyol and a combination of polyols, the polyol being glycerol / propylene glycol / sorbitol / mannitol / xylitol / arabitol / ribitol / erytriol / polyvinyl alcohol / polyethylene glycol / polybutylene glycol / polypropylene glycol / polyethylene glycol / polypropylene glycol, the concentration of polyols in the drug solution is greater than 10%, the drug solution is used to treat affected tissue, the affected tissue may be bacterially infected tissue / necrotic tissue / fungally infected tissue / tissue containing fluids with many toxins / benign tumors / cancerous tumors.

14. A drug having components and effects for use for the purpose described in claim 13, wherein the drug solution has a glycerol concentration of more than 30%.

15. A drug having components and effects for use for the purpose described in claim 10, wherein the peroxide in the drug is H2O2 / urea peroxide / MEK peroxide.

16. A drug having components and effects used for the purposes described in any one of claims 1 to 9 and 12 to 15, wherein the drug is used for human purposes or for livestock or wild animals.

17. A drug having components and effects for use for any one of claims 1 to 10, wherein the drug is combined with water / a solution containing NaCl / other liquids to form a liquid product for use by intramuscular / intravenous injection / arterial injection / intravenous drip infusion / intra-arterial drip infusion / rectal administration / nasal spray / alveolar spray / eye drops / spray or application to the skin / spray or application to wounds / spray or application to infected tissue having open wounds, or the drug is made in the form of a chelating drug candy for oral ingestion / rectal insertion.

18. A drug having components and effects used for the purposes described in any one of claims 1 to 10, wherein the drug is instructed to be used in conjunction with the use of other drugs.

19. A drug having components and effects used for the purposes described in any one of claims 1 to 10, wherein the drug is prescribed for use for at least two periods per year, with each period separated by at least four months.

20. A drug having components and effects used for the purposes described in any one of claims 1 to 9, wherein the drug is introduced into a beverage / food / processed food / drinking water / spice / vitamin supplement, and the host is a human / animal, so that the active ingredient of the drug is always present in the host's body and helps to strengthen the host's immune system / reduces the accumulation of Zn ions and other heavy metal ions in the host's body / improves the host's health.

21. A drug having ingredients and effects used for the purposes of any one of claims 1 to 9, which is introduced into cosmetics to reduce the accumulation of Zn ions / other transition metal ions on the skin, to prevent the growth of microorganisms on the skin, and to improve the biological / chemical / physical properties of the skin.

22. A drug having components and effects for use for the purpose of claim 21, wherein the cosmetic containing the drug has an additional salt formed from a fatty acid / ricinoleic acid / aryl sulfone / alkyl sulfonic acid and a polyamine.

23. A drug having components and effects used for the purposes of any one of claims 1 to 10, wherein the drug is combined with water to form an environmental treatment solution / is introduced into an environmental treatment solution to form a solution containing the active component of the drug for environmental treatment.

24. A drug having components and effects used for the purposes described in any one of claims 1 to 9, wherein the drug is introduced into a body hygiene product, and the body hygiene product may be a mouthwash / eye drops / shampoo / shower oil / bath soap / hand soap / hand sanitizer / liquid alcohol disinfectant solution.

25. A drug having components and effects used for the purposes described in any one of claims 1 to 9, wherein the drug is combined with water / other liquids for use in preserving living tissue awaiting transplantation.

26. A drug having components and effects used for the purposes of any one of claims 1 to 9, wherein the drug is used to preserve blood / artificial blood for transfusion, and at the same time, such that the blood / artificial blood has the ability to prevent and treat the disease described in claim 1.

27. A drug having components and effects used for the purposes described in any one of claims 1 to 14, wherein the drug is used in surgery to prevent blood coagulation / to prevent infection of a surgical wound.

Images